#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Disturbances across whole brain networks during reward anticipation in an abstinent addiction population Graphical abstract Network based statistics (NBS) analyses detected a graph sub-network comprising 153 edges between 59 nodes of the connectome where the ADD group demonstrated significantly less connectivity compared with the CON group.
1-1	0-12	Disturbances	_
1-2	13-19	across	_
1-3	20-25	whole	_
1-4	26-31	brain	_
1-5	32-40	networks	_
1-6	41-47	during	_
1-7	48-54	reward	_
1-8	55-67	anticipation	_
1-9	68-70	in	_
1-10	71-73	an	_
1-11	74-83	abstinent	_
1-12	84-93	addiction	_
1-13	94-104	population	_
1-14	105-114	Graphical	_
1-15	115-123	abstract	_
1-16	124-131	Network	_
1-17	132-137	based	_
1-18	138-148	statistics	_
1-19	149-150	(	_
1-20	151-154	NBS	_
1-21	155-156	)	_
1-22	157-165	analyses	_
1-23	166-174	detected	_
1-24	175-176	a	_
1-25	177-182	graph	_
1-26	183-194	sub-network	_
1-27	195-205	comprising	_
1-28	206-209	153	_
1-29	210-215	edges	_
1-30	216-223	between	_
1-31	224-226	59	_
1-32	227-232	nodes	_
1-33	233-235	of	_
1-34	236-239	the	_
1-35	240-250	connectome	_
1-36	251-256	where	_
1-37	257-260	the	_
1-38	261-264	ADD	_
1-39	265-270	group	_
1-40	271-283	demonstrated	_
1-41	284-297	significantly	_
1-42	298-302	less	_
1-43	303-315	connectivity	_
1-44	316-324	compared	_
1-45	325-329	with	_
1-46	330-333	the	_
1-47	334-337	CON	_
1-48	338-343	group	_
1-49	344-345	.	_

Text=These differences in connectivity were mostly intra-hemispheric (55%), the majority (38%) being in the right hemisphere.
2-1	346-351	These	_
2-2	352-363	differences	_
2-3	364-366	in	_
2-4	367-379	connectivity	_
2-5	380-384	were	_
2-6	385-391	mostly	_
2-7	392-409	intra-hemispheric	_
2-8	410-411	(	_
2-9	412-414	55	_
2-10	415-416	%	_
2-11	417-418	)	_
2-12	419-420	,	_
2-13	421-424	the	_
2-14	425-433	majority	_
2-15	434-435	(	_
2-16	436-438	38	_
2-17	439-440	%	_
2-18	441-442	)	_
2-19	443-448	being	_
2-20	449-451	in	_
2-21	452-455	the	_
2-22	456-461	right	_
2-23	462-472	hemisphere	_
2-24	473-474	.	_

Text=The anatomical distribution of these connectivity differences between the two groups involved frontal (insula, inferior frontal gyrus, orbitofrontal cortex), limbic-associated (anterior cingulate gyrus, thalamus), and striatal (accumbens, caudate, pallidum) regions.
3-1	475-478	The	_
3-2	479-489	anatomical	_
3-3	490-502	distribution	_
3-4	503-505	of	_
3-5	506-511	these	_
3-6	512-524	connectivity	_
3-7	525-536	differences	_
3-8	537-544	between	_
3-9	545-548	the	_
3-10	549-552	two	_
3-11	553-559	groups	_
3-12	560-568	involved	_
3-13	569-576	frontal	_
3-14	577-578	(	_
3-15	579-585	insula	_
3-16	586-587	,	_
3-17	588-596	inferior	_
3-18	597-604	frontal	_
3-19	605-610	gyrus	_
3-20	611-612	,	_
3-21	613-626	orbitofrontal	_
3-22	627-633	cortex	_
3-23	634-635	)	_
3-24	636-637	,	_
3-25	638-655	limbic-associated	_
3-26	656-657	(	_
3-27	658-666	anterior	_
3-28	667-676	cingulate	_
3-29	677-682	gyrus	_
3-30	683-684	,	_
3-31	685-693	thalamus	_
3-32	694-695	)	_
3-33	696-697	,	_
3-34	698-701	and	_
3-35	702-710	striatal	_
3-36	711-712	(	_
3-37	713-722	accumbens	_
3-38	723-724	,	_
3-39	725-732	caudate	_
3-40	733-734	,	_
3-41	735-743	pallidum	_
3-42	744-745	)	_
3-43	746-753	regions	_
3-44	754-755	.	_

Text=The connectivity differences reported in this ADD sample indicate alterations between cognitive, striatal and limbic-associated regions during reward anticipation that persist into extended abstinence.
4-1	756-759	The	_
4-2	760-772	connectivity	_
4-3	773-784	differences	_
4-4	785-793	reported	_
4-5	794-796	in	_
4-6	797-801	this	_
4-7	802-805	ADD	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
4-8	806-812	sample	_
4-9	813-821	indicate	_
4-10	822-833	alterations	_
4-11	834-841	between	_
4-12	842-851	cognitive	_
4-13	852-853	,	_
4-14	854-862	striatal	_
4-15	863-866	and	_
4-16	867-884	limbic-associated	_
4-17	885-892	regions	_
4-18	893-899	during	_
4-19	900-906	reward	_
4-20	907-919	anticipation	_
4-21	920-924	that	_
4-22	925-932	persist	_
4-23	933-937	into	_
4-24	938-946	extended	_
4-25	947-957	abstinence	_
4-26	958-959	.	_

Text=Highlights Analytical methods can capture key features of whole brain networks in addiction.
5-1	960-970	Highlights	_
5-2	971-981	Analytical	_
5-3	982-989	methods	_
5-4	990-993	can	_
5-5	994-1001	capture	_
5-6	1002-1005	key	_
5-7	1006-1014	features	_
5-8	1015-1017	of	_
5-9	1018-1023	whole	_
5-10	1024-1029	brain	_
5-11	1030-1038	networks	_
5-12	1039-1041	in	_
5-13	1042-1051	addiction	_
5-14	1052-1053	.	_

Text=We compared reward network connectivity in addiction (ADD) and control (CON) groups.
6-1	1054-1056	We	_
6-2	1057-1065	compared	_
6-3	1066-1072	reward	_
6-4	1073-1080	network	_
6-5	1081-1093	connectivity	_
6-6	1094-1096	in	_
6-7	1097-1106	addiction	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
6-8	1107-1108	(	_
6-9	1109-1112	ADD	_
6-10	1113-1114	)	_
6-11	1115-1118	and	_
6-12	1119-1126	control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
6-13	1127-1128	(	_
6-14	1129-1132	CON	_
6-15	1133-1134	)	_
6-16	1135-1141	groups	_
6-17	1142-1143	.	_

Text=The ADD group showed disruptions in global network connectivity.
7-1	1144-1147	The	_
7-2	1148-1151	ADD	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
7-3	1152-1157	group	_
7-4	1158-1164	showed	_
7-5	1165-1176	disruptions	_
7-6	1177-1179	in	_
7-7	1180-1186	global	_
7-8	1187-1194	network	_
7-9	1195-1207	connectivity	_
7-10	1208-1209	.	_

Text=Global network measures may be more sensitive than traditional voxel-wise analyses.
8-1	1210-1216	Global	_
8-2	1217-1224	network	_
8-3	1225-1233	measures	_
8-4	1234-1237	may	_
8-5	1238-1240	be	_
8-6	1241-1245	more	_
8-7	1246-1255	sensitive	_
8-8	1256-1260	than	_
8-9	1261-1272	traditional	_
8-10	1273-1283	voxel-wise	_
8-11	1284-1292	analyses	_
8-12	1293-1294	.	_

Text=The prevalent spatial distribution of abnormalities reported in cognitive fMRI studies in addiction suggests there are extensive disruptions across whole brain networks.
9-1	1295-1298	The	_
9-2	1299-1308	prevalent	_
9-3	1309-1316	spatial	_
9-4	1317-1329	distribution	_
9-5	1330-1332	of	_
9-6	1333-1346	abnormalities	_
9-7	1347-1355	reported	_
9-8	1356-1358	in	_
9-9	1359-1368	cognitive	http://maven.renci.org/NeuroBridge/neurobridge#MildCognitiveDisorder
9-10	1369-1373	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#MildCognitiveDisorder
9-11	1374-1381	studies	_
9-12	1382-1384	in	_
9-13	1385-1394	addiction	_
9-14	1395-1403	suggests	_
9-15	1404-1409	there	_
9-16	1410-1413	are	_
9-17	1414-1423	extensive	_
9-18	1424-1435	disruptions	_
9-19	1436-1442	across	_
9-20	1443-1448	whole	_
9-21	1449-1454	brain	_
9-22	1455-1463	networks	_
9-23	1464-1465	.	_

Text=Studies using resting state have reported disruptions in network connectivity in addiction, but these studies have not revealed characteristics of network functioning during critical psychological processes that are disrupted in addiction populations.
10-1	1466-1473	Studies	_
10-2	1474-1479	using	_
10-3	1480-1487	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
10-4	1488-1493	state	_
10-5	1494-1498	have	_
10-6	1499-1507	reported	_
10-7	1508-1519	disruptions	_
10-8	1520-1522	in	_
10-9	1523-1530	network	_
10-10	1531-1543	connectivity	_
10-11	1544-1546	in	_
10-12	1547-1556	addiction	_
10-13	1557-1558	,	_
10-14	1559-1562	but	_
10-15	1563-1568	these	_
10-16	1569-1576	studies	_
10-17	1577-1581	have	_
10-18	1582-1585	not	_
10-19	1586-1594	revealed	_
10-20	1595-1610	characteristics	_
10-21	1611-1613	of	_
10-22	1614-1621	network	_
10-23	1622-1633	functioning	_
10-24	1634-1640	during	_
10-25	1641-1649	critical	_
10-26	1650-1663	psychological	_
10-27	1664-1673	processes	_
10-28	1674-1678	that	_
10-29	1679-1682	are	_
10-30	1683-1692	disrupted	_
10-31	1693-1695	in	_
10-32	1696-1705	addiction	_
10-33	1706-1717	populations	_
10-34	1718-1719	.	_

Text=Analytic methods that can capture key features of whole brain networks during psychological processes may be more sensitive in revealing additional and widespread neural disturbances in addiction, that are the provisions for relapse risk, and targets for medication development.
11-1	1720-1728	Analytic	_
11-2	1729-1736	methods	_
11-3	1737-1741	that	_
11-4	1742-1745	can	_
11-5	1746-1753	capture	_
11-6	1754-1757	key	_
11-7	1758-1766	features	_
11-8	1767-1769	of	_
11-9	1770-1775	whole	_
11-10	1776-1781	brain	_
11-11	1782-1790	networks	_
11-12	1791-1797	during	_
11-13	1798-1811	psychological	_
11-14	1812-1821	processes	_
11-15	1822-1825	may	_
11-16	1826-1828	be	_
11-17	1829-1833	more	_
11-18	1834-1843	sensitive	_
11-19	1844-1846	in	_
11-20	1847-1856	revealing	_
11-21	1857-1867	additional	_
11-22	1868-1871	and	_
11-23	1872-1882	widespread	_
11-24	1883-1889	neural	_
11-25	1890-1902	disturbances	_
11-26	1903-1905	in	_
11-27	1906-1915	addiction	_
11-28	1916-1917	,	_
11-29	1918-1922	that	_
11-30	1923-1926	are	_
11-31	1927-1930	the	_
11-32	1931-1941	provisions	_
11-33	1942-1945	for	_
11-34	1946-1953	relapse	_
11-35	1954-1958	risk	_
11-36	1959-1960	,	_
11-37	1961-1964	and	_
11-38	1965-1972	targets	_
11-39	1973-1976	for	_
11-40	1977-1987	medication	_
11-41	1988-1999	development	_
11-42	2000-2001	.	_

Text=The current study compared a substance addiction (ADD; n = 83) group in extended abstinence with a control (CON; n = 68) group on functional MRI (voxel-wise activation) and global network (connectivity) measures related to reward anticipation on a monetary incentive delay task.
12-1	2002-2005	The	_
12-2	2006-2013	current	_
12-3	2014-2019	study	_
12-4	2020-2028	compared	_
12-5	2029-2030	a	_
12-6	2031-2040	substance	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceAbuse
12-7	2041-2050	addiction	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceAbuse
12-8	2051-2052	(	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceAbuse
12-9	2053-2056	ADD	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceAbuse
12-10	2057-2058	;	_
12-11	2059-2060	n	_
12-12	2061-2062	=	_
12-13	2063-2065	83	_
12-14	2066-2067	)	_
12-15	2068-2073	group	_
12-16	2074-2076	in	_
12-17	2077-2085	extended	_
12-18	2086-2096	abstinence	_
12-19	2097-2101	with	_
12-20	2102-2103	a	_
12-21	2104-2111	control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
12-22	2112-2113	(	_
12-23	2114-2117	CON	_
12-24	2118-2119	;	_
12-25	2120-2121	n	_
12-26	2122-2123	=	_
12-27	2124-2126	68	_
12-28	2127-2128	)	_
12-29	2129-2134	group	_
12-30	2135-2137	on	_
12-31	2138-2148	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
12-32	2149-2152	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
12-33	2153-2154	(	_
12-34	2155-2165	voxel-wise	_
12-35	2166-2176	activation	_
12-36	2177-2178	)	_
12-37	2179-2182	and	_
12-38	2183-2189	global	_
12-39	2190-2197	network	_
12-40	2198-2199	(	_
12-41	2200-2212	connectivity	_
12-42	2213-2214	)	_
12-43	2215-2223	measures	_
12-44	2224-2231	related	_
12-45	2232-2234	to	_
12-46	2235-2241	reward	_
12-47	2242-2254	anticipation	_
12-48	2255-2257	on	_
12-49	2258-2259	a	_
12-50	2260-2268	monetary	_
12-51	2269-2278	incentive	_
12-52	2279-2284	delay	_
12-53	2285-2289	task	_
12-54	2290-2291	.	_

Text=In the absence of group differences on MID performance, the ADD group showed reduced activation predominantly across temporal and visual regions, but not across the striatum.
13-1	2292-2294	In	_
13-2	2295-2298	the	_
13-3	2299-2306	absence	_
13-4	2307-2309	of	_
13-5	2310-2315	group	_
13-6	2316-2327	differences	_
13-7	2328-2330	on	_
13-8	2331-2334	MID	http://maven.renci.org/NeuroBridge/neurobridge#ExtrapyramidalDisease
13-9	2335-2346	performance	_
13-10	2347-2348	,	_
13-11	2349-2352	the	_
13-12	2353-2356	ADD	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
13-13	2357-2362	group	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
13-14	2363-2369	showed	_
13-15	2370-2377	reduced	_
13-16	2378-2388	activation	_
13-17	2389-2402	predominantly	_
13-18	2403-2409	across	_
13-19	2410-2418	temporal	_
13-20	2419-2422	and	_
13-21	2423-2429	visual	_
13-22	2430-2437	regions	_
13-23	2438-2439	,	_
13-24	2440-2443	but	_
13-25	2444-2447	not	_
13-26	2448-2454	across	_
13-27	2455-2458	the	_
13-28	2459-2467	striatum	_
13-29	2468-2469	.	_

Text=The ADD group also showed disruptions in global network connectivity (lower clustering coefficient and higher characteristic path length), and significantly less connectivity across a sub-network comprising frontal, temporal, limbic and striatal nodes.
14-1	2470-2473	The	_
14-2	2474-2477	ADD	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
14-3	2478-2483	group	_
14-4	2484-2488	also	_
14-5	2489-2495	showed	_
14-6	2496-2507	disruptions	_
14-7	2508-2510	in	_
14-8	2511-2517	global	_
14-9	2518-2525	network	_
14-10	2526-2538	connectivity	_
14-11	2539-2540	(	_
14-12	2541-2546	lower	_
14-13	2547-2557	clustering	_
14-14	2558-2569	coefficient	_
14-15	2570-2573	and	_
14-16	2574-2580	higher	_
14-17	2581-2595	characteristic	_
14-18	2596-2600	path	_
14-19	2601-2607	length	_
14-20	2608-2609	)	_
14-21	2610-2611	,	_
14-22	2612-2615	and	_
14-23	2616-2629	significantly	_
14-24	2630-2634	less	_
14-25	2635-2647	connectivity	_
14-26	2648-2654	across	_
14-27	2655-2656	a	_
14-28	2657-2668	sub-network	_
14-29	2669-2679	comprising	_
14-30	2680-2687	frontal	_
14-31	2688-2689	,	_
14-32	2690-2698	temporal	_
14-33	2699-2700	,	_
14-34	2701-2707	limbic	_
14-35	2708-2711	and	_
14-36	2712-2720	striatal	_
14-37	2721-2726	nodes	_
14-38	2727-2728	.	_

Text=These results show that an addiction group in extended abstinence exhibit localised disruptions in brain activation, but more extensive disturbances in functional connectivity across whole brain networks.
15-1	2729-2734	These	_
15-2	2735-2742	results	_
15-3	2743-2747	show	_
15-4	2748-2752	that	_
15-5	2753-2755	an	_
15-6	2756-2765	addiction	_
15-7	2766-2771	group	_
15-8	2772-2774	in	_
15-9	2775-2783	extended	_
15-10	2784-2794	abstinence	_
15-11	2795-2802	exhibit	_
15-12	2803-2812	localised	_
15-13	2813-2824	disruptions	_
15-14	2825-2827	in	_
15-15	2828-2833	brain	_
15-16	2834-2844	activation	_
15-17	2845-2846	,	_
15-18	2847-2850	but	_
15-19	2851-2855	more	_
15-20	2856-2865	extensive	_
15-21	2866-2878	disturbances	_
15-22	2879-2881	in	_
15-23	2882-2892	functional	_
15-24	2893-2905	connectivity	_
15-25	2906-2912	across	_
15-26	2913-2918	whole	_
15-27	2919-2924	brain	_
15-28	2925-2933	networks	_
15-29	2934-2935	.	_

Text=We propose that measures of global network functioning may be more sensitive in highlighting latent and more widespread neural disruptions during critical psychological processes in addiction and other psychiatric disorders.
16-1	2936-2938	We	_
16-2	2939-2946	propose	_
16-3	2947-2951	that	_
16-4	2952-2960	measures	_
16-5	2961-2963	of	_
16-6	2964-2970	global	_
16-7	2971-2978	network	_
16-8	2979-2990	functioning	_
16-9	2991-2994	may	_
16-10	2995-2997	be	_
16-11	2998-3002	more	_
16-12	3003-3012	sensitive	_
16-13	3013-3015	in	_
16-14	3016-3028	highlighting	_
16-15	3029-3035	latent	_
16-16	3036-3039	and	_
16-17	3040-3044	more	_
16-18	3045-3055	widespread	_
16-19	3056-3062	neural	_
16-20	3063-3074	disruptions	_
16-21	3075-3081	during	_
16-22	3082-3090	critical	_
16-23	3091-3104	psychological	_
16-24	3105-3114	processes	_
16-25	3115-3117	in	_
16-26	3118-3127	addiction	_
16-27	3128-3131	and	_
16-28	3132-3137	other	_
16-29	3138-3149	psychiatric	_
16-30	3150-3159	disorders	_
16-31	3160-3161	.	_

Text=Material and methods Participants Sixty-eight control (CON: mean age 39.79 ± 1.22; 18 females, 50 males) and 83 addiction (ADD: mean age 40.05 ± 0.92; 16 females, 67 males) participants completed the current study.
17-1	3162-3170	Material	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
17-2	3171-3174	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
17-3	3175-3182	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
17-4	3183-3195	Participants	_
17-5	3196-3207	Sixty-eight	_
17-6	3208-3215	control	_
17-7	3216-3217	(	_
17-8	3218-3221	CON	_
17-9	3222-3223	:	_
17-10	3224-3228	mean	_
17-11	3229-3232	age	_
17-12	3233-3238	39.79	_
17-13	3239-3240	±	_
17-14	3241-3245	1.22	_
17-15	3246-3247	;	_
17-16	3248-3250	18	_
17-17	3251-3258	females	_
17-18	3259-3260	,	_
17-19	3261-3263	50	_
17-20	3264-3269	males	_
17-21	3270-3271	)	_
17-22	3272-3275	and	_
17-23	3276-3278	83	_
17-24	3279-3288	addiction	_
17-25	3289-3290	(	_
17-26	3291-3294	ADD	_
17-27	3295-3296	:	_
17-28	3297-3301	mean	_
17-29	3302-3305	age	_
17-30	3306-3311	40.05	_
17-31	3312-3313	±	_
17-32	3314-3318	0.92	_
17-33	3319-3320	;	_
17-34	3321-3323	16	_
17-35	3324-3331	females	_
17-36	3332-3333	,	_
17-37	3334-3336	67	_
17-38	3337-3342	males	_
17-39	3343-3344	)	_
17-40	3345-3357	participants	_
17-41	3358-3367	completed	_
17-42	3368-3371	the	_
17-43	3372-3379	current	_
17-44	3380-3385	study	_
17-45	3386-3387	.	_

Text=The current dataset was collected as part of a multi-centre study involving three study sites in the United Kingdom (Imperial College London, University of Cambridge and University of Manchester – ICCAM).
18-1	3388-3391	The	_
18-2	3392-3399	current	_
18-3	3400-3407	dataset	_
18-4	3408-3411	was	_
18-5	3412-3421	collected	_
18-6	3422-3424	as	_
18-7	3425-3429	part	_
18-8	3430-3432	of	_
18-9	3433-3434	a	_
18-10	3435-3447	multi-centre	_
18-11	3448-3453	study	_
18-12	3454-3463	involving	_
18-13	3464-3469	three	_
18-14	3470-3475	study	_
18-15	3476-3481	sites	_
18-16	3482-3484	in	_
18-17	3485-3488	the	_
18-18	3489-3495	United	_
18-19	3496-3503	Kingdom	_
18-20	3504-3505	(	_
18-21	3506-3514	Imperial	_
18-22	3515-3522	College	_
18-23	3523-3529	London	_
18-24	3530-3531	,	_
18-25	3532-3542	University	_
18-26	3543-3545	of	_
18-27	3546-3555	Cambridge	_
18-28	3556-3559	and	_
18-29	3560-3570	University	_
18-30	3571-3573	of	_
18-31	3574-3584	Manchester	_
18-32	3585-3586	–	_
18-33	3587-3592	ICCAM	_
18-34	3593-3594	)	_
18-35	3595-3596	.	_

Text=For a more detailed description of the ICCAM Platform, see) and.
19-1	3597-3600	For	_
19-2	3601-3602	a	_
19-3	3603-3607	more	_
19-4	3608-3616	detailed	_
19-5	3617-3628	description	_
19-6	3629-3631	of	_
19-7	3632-3635	the	_
19-8	3636-3641	ICCAM	_
19-9	3642-3650	Platform	_
19-10	3651-3652	,	_
19-11	3653-3656	see	_
19-12	3657-3658	)	_
19-13	3659-3662	and	_
19-14	3663-3664	.	_

Text=Inclusion criteria were individuals who met DSM-IV measures for current or prior substance dependence (e.g., alcohol, cocaine, opiates).
20-1	3665-3674	Inclusion	_
20-2	3675-3683	criteria	_
20-3	3684-3688	were	_
20-4	3689-3700	individuals	_
20-5	3701-3704	who	_
20-6	3705-3708	met	_
20-7	3709-3715	DSM-IV	_
20-8	3716-3724	measures	_
20-9	3725-3728	for	_
20-10	3729-3736	current	_
20-11	3737-3739	or	_
20-12	3740-3745	prior	_
20-13	3746-3755	substance	_
20-14	3756-3766	dependence	_
20-15	3767-3768	(	_
20-16	3769-3773	e.g.	_
20-17	3774-3775	,	_
20-18	3776-3783	alcohol	_
20-19	3784-3785	,	_
20-20	3786-3793	cocaine	_
20-21	3794-3795	,	_
20-22	3796-3803	opiates	_
20-23	3804-3805	)	_
20-24	3806-3807	.	_

Text=The ADD group consisted of 29 (35%) pure alcohol-dependent, 42 (50%) poly substance-dependent (e.g., alcohol and cocaine, cocaine and opiate) and 12 (15%) mono substance-dependent (e.g., cocaine, opiates) volunteers.
21-1	3808-3811	The	_
21-2	3812-3815	ADD	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
21-3	3816-3821	group	_
21-4	3822-3831	consisted	_
21-5	3832-3834	of	_
21-6	3835-3837	29	_
21-7	3838-3839	(	_
21-8	3840-3842	35	_
21-9	3843-3844	%	_
21-10	3845-3846	)	_
21-11	3847-3851	pure	http://maven.renci.org/NeuroBridge/neurobridge#AirAudiometer
21-12	3852-3869	alcohol-dependent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
21-13	3870-3871	,	_
21-14	3872-3874	42	_
21-15	3875-3876	(	_
21-16	3877-3879	50	_
21-17	3880-3881	%	_
21-18	3882-3883	)	_
21-19	3884-3888	poly	_
21-20	3889-3908	substance-dependent	_
21-21	3909-3910	(	_
21-22	3911-3915	e.g.	_
21-23	3916-3917	,	_
21-24	3918-3925	alcohol	_
21-25	3926-3929	and	_
21-26	3930-3937	cocaine	_
21-27	3938-3939	,	_
21-28	3940-3947	cocaine	_
21-29	3948-3951	and	_
21-30	3952-3958	opiate	_
21-31	3959-3960	)	_
21-32	3961-3964	and	_
21-33	3965-3967	12	_
21-34	3968-3969	(	_
21-35	3970-3972	15	_
21-36	3973-3974	%	_
21-37	3975-3976	)	_
21-38	3977-3981	mono	_
21-39	3982-4001	substance-dependent	_
21-40	4002-4003	(	_
21-41	4004-4008	e.g.	_
21-42	4009-4010	,	_
21-43	4011-4018	cocaine	_
21-44	4019-4020	,	_
21-45	4021-4028	opiates	_
21-46	4029-4030	)	_
21-47	4031-4041	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#AbnormalInvoluntaryMovementScale
21-48	4042-4043	.	_

Text=While addiction studies typically recruit volunteers in early abstinence, there was no upper limit in the current study.
22-1	4044-4049	While	_
22-2	4050-4059	addiction	_
22-3	4060-4067	studies	_
22-4	4068-4077	typically	_
22-5	4078-4085	recruit	_
22-6	4086-4096	volunteers	_
22-7	4097-4099	in	_
22-8	4100-4105	early	_
22-9	4106-4116	abstinence	_
22-10	4117-4118	,	_
22-11	4119-4124	there	_
22-12	4125-4128	was	_
22-13	4129-4131	no	_
22-14	4132-4137	upper	_
22-15	4138-4143	limit	_
22-16	4144-4146	in	_
22-17	4147-4150	the	_
22-18	4151-4158	current	_
22-19	4159-4164	study	_
22-20	4165-4166	.	_

Text=The mean abstinence length from alcohol in the current sample was 15.00 ± 3.50 months, while for cocaine and opiates it was 27.99 ± 3.72 and 39.04 ± 7.75 months, respectively.
23-1	4167-4170	The	_
23-2	4171-4175	mean	_
23-3	4176-4186	abstinence	_
23-4	4187-4193	length	_
23-5	4194-4198	from	_
23-6	4199-4206	alcohol	_
23-7	4207-4209	in	_
23-8	4210-4213	the	_
23-9	4214-4221	current	_
23-10	4222-4228	sample	_
23-11	4229-4232	was	_
23-12	4233-4238	15.00	_
23-13	4239-4240	±	_
23-14	4241-4245	3.50	_
23-15	4246-4252	months	_
23-16	4253-4254	,	_
23-17	4255-4260	while	_
23-18	4261-4264	for	_
23-19	4265-4272	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
23-20	4273-4276	and	_
23-21	4277-4284	opiates	_
23-22	4285-4287	it	_
23-23	4288-4291	was	_
23-24	4292-4297	27.99	_
23-25	4298-4299	±	_
23-26	4300-4304	3.72	_
23-27	4305-4308	and	_
23-28	4309-4314	39.04	_
23-29	4315-4316	±	_
23-30	4317-4321	7.75	_
23-31	4322-4328	months	_
23-32	4329-4330	,	_
23-33	4331-4343	respectively	_
23-34	4344-4345	.	_

Text=Therefore, the current ADD group was made of a heterogenous sample with former substance-dependencies, and with variable levels of substance abstinence at the time of testing.
24-1	4346-4355	Therefore	_
24-2	4356-4357	,	_
24-3	4358-4361	the	_
24-4	4362-4369	current	_
24-5	4370-4373	ADD	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
24-6	4374-4379	group	_
24-7	4380-4383	was	_
24-8	4384-4388	made	_
24-9	4389-4391	of	_
24-10	4392-4393	a	_
24-11	4394-4406	heterogenous	_
24-12	4407-4413	sample	_
24-13	4414-4418	with	_
24-14	4419-4425	former	_
24-15	4426-4448	substance-dependencies	_
24-16	4449-4450	,	_
24-17	4451-4454	and	_
24-18	4455-4459	with	_
24-19	4460-4468	variable	_
24-20	4469-4475	levels	_
24-21	4476-4478	of	_
24-22	4479-4488	substance	_
24-23	4489-4499	abstinence	_
24-24	4500-4502	at	_
24-25	4503-4506	the	_
24-26	4507-4511	time	_
24-27	4512-4514	of	_
24-28	4515-4522	testing	_
24-29	4523-4524	.	_

Text=This meant that there was no substance dependence measure that was shared by all members of the ADD group.
25-1	4525-4529	This	_
25-2	4530-4535	meant	_
25-3	4536-4540	that	_
25-4	4541-4546	there	_
25-5	4547-4550	was	_
25-6	4551-4553	no	_
25-7	4554-4563	substance	_
25-8	4564-4574	dependence	_
25-9	4575-4582	measure	_
25-10	4583-4587	that	_
25-11	4588-4591	was	_
25-12	4592-4598	shared	_
25-13	4599-4601	by	_
25-14	4602-4605	all	_
25-15	4606-4613	members	_
25-16	4614-4616	of	_
25-17	4617-4620	the	_
25-18	4621-4624	ADD	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
25-19	4625-4630	group	_
25-20	4631-4632	.	_

Text=The CON group had no previous history of substance abuse, as assessed using the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) and timeline follow-back.
26-1	4633-4636	The	_
26-2	4637-4640	CON	http://maven.renci.org/NeuroBridge/neurobridge#Continuous
26-3	4641-4646	group	_
26-4	4647-4650	had	_
26-5	4651-4653	no	_
26-6	4654-4662	previous	_
26-7	4663-4670	history	_
26-8	4671-4673	of	_
26-9	4674-4683	substance	_
26-10	4684-4689	abuse	_
26-11	4690-4691	,	_
26-12	4692-4694	as	_
26-13	4695-4703	assessed	_
26-14	4704-4709	using	_
26-15	4710-4713	the	_
26-16	4714-4721	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#BloodSubstanceMeasurement
26-17	4722-4723	,	http://maven.renci.org/NeuroBridge/neurobridge#BloodSubstanceMeasurement
26-18	4724-4731	Smoking	http://maven.renci.org/NeuroBridge/neurobridge#BloodSubstanceMeasurement
26-19	4732-4735	and	http://maven.renci.org/NeuroBridge/neurobridge#BloodSubstanceMeasurement
26-20	4736-4745	Substance	http://maven.renci.org/NeuroBridge/neurobridge#BloodSubstanceMeasurement
26-21	4746-4757	Involvement	http://maven.renci.org/NeuroBridge/neurobridge#BloodSubstanceMeasurement
26-22	4758-4767	Screening	http://maven.renci.org/NeuroBridge/neurobridge#BloodSubstanceMeasurement
26-23	4768-4772	Test	http://maven.renci.org/NeuroBridge/neurobridge#BloodSubstanceMeasurement
26-24	4773-4774	(	http://maven.renci.org/NeuroBridge/neurobridge#BloodSubstanceMeasurement
26-25	4775-4781	ASSIST	http://maven.renci.org/NeuroBridge/neurobridge#BloodSubstanceMeasurement
26-26	4782-4783	)	http://maven.renci.org/NeuroBridge/neurobridge#BloodSubstanceMeasurement
26-27	4784-4787	and	_
26-28	4788-4796	timeline	_
26-29	4797-4808	follow-back	_
26-30	4809-4810	.	_

Text=All participants were required to provide a negative breath alcohol test and a negative urine sample for various drugs of abuse on the day of testing (screening for the presence of amphetamines, benzodiazepines, cannabinoids, cocaine and opiates).
27-1	4811-4814	All	_
27-2	4815-4827	participants	_
27-3	4828-4832	were	_
27-4	4833-4841	required	_
27-5	4842-4844	to	_
27-6	4845-4852	provide	_
27-7	4853-4854	a	_
27-8	4855-4863	negative	_
27-9	4864-4870	breath	_
27-10	4871-4878	alcohol	_
27-11	4879-4883	test	_
27-12	4884-4887	and	_
27-13	4888-4889	a	_
27-14	4890-4898	negative	_
27-15	4899-4904	urine	_
27-16	4905-4911	sample	_
27-17	4912-4915	for	_
27-18	4916-4923	various	_
27-19	4924-4929	drugs	_
27-20	4930-4932	of	_
27-21	4933-4938	abuse	_
27-22	4939-4941	on	_
27-23	4942-4945	the	_
27-24	4946-4949	day	_
27-25	4950-4952	of	_
27-26	4953-4960	testing	_
27-27	4961-4962	(	_
27-28	4963-4972	screening	_
27-29	4973-4976	for	_
27-30	4977-4980	the	_
27-31	4981-4989	presence	_
27-32	4990-4992	of	_
27-33	4993-5005	amphetamines	_
27-34	5006-5007	,	_
27-35	5008-5023	benzodiazepines	_
27-36	5024-5025	,	_
27-37	5026-5038	cannabinoids	_
27-38	5039-5040	,	_
27-39	5041-5048	cocaine	_
27-40	5049-5052	and	_
27-41	5053-5060	opiates	_
27-42	5061-5062	)	_
27-43	5063-5064	.	_

Text=The Mini-International Neuropsychiatric Interview (MINI) was administered to all participants by a trained psychiatrist to screen for the presence of Axis I psychiatric disorders that were part of the study exclusion criteria.
28-1	5065-5068	The	_
28-2	5069-5087	Mini-International	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
28-3	5088-5104	Neuropsychiatric	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
28-4	5105-5114	Interview	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
28-5	5115-5116	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
28-6	5117-5121	MINI	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
28-7	5122-5123	)	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
28-8	5124-5127	was	_
28-9	5128-5140	administered	_
28-10	5141-5143	to	_
28-11	5144-5147	all	_
28-12	5148-5160	participants	_
28-13	5161-5163	by	_
28-14	5164-5165	a	_
28-15	5166-5173	trained	_
28-16	5174-5186	psychiatrist	_
28-17	5187-5189	to	_
28-18	5190-5196	screen	_
28-19	5197-5200	for	_
28-20	5201-5204	the	_
28-21	5205-5213	presence	_
28-22	5214-5216	of	_
28-23	5217-5221	Axis	_
28-24	5222-5223	I	_
28-25	5224-5235	psychiatric	_
28-26	5236-5245	disorders	_
28-27	5246-5250	that	_
28-28	5251-5255	were	_
28-29	5256-5260	part	_
28-30	5261-5263	of	_
28-31	5264-5267	the	_
28-32	5268-5273	study	_
28-33	5274-5283	exclusion	_
28-34	5284-5292	criteria	_
28-35	5293-5294	.	_

Text=Exclusion criteria included 1) current use of regular prescription or non-prescription medication that could not be stopped; 2) current primary axis I diagnosis, past history of psychosis (unless drug-induced); 3) current or past history of enduring severe mental illness (e.g., schizophrenia, bipolar affective disorder); 4) other current or past psychiatric history that, in the opinion of a psychiatrist, contraindicated participation; 5) history or presence of a significant neurological diagnosis that may have influenced the outcome or analysis of the results; 6) claustrophobia or unable to lie still in the MRI scanner for up to 90 min and 7) presence of a cardiac pacemaker, other electronic device or other MRI contraindication, including pregnancy, as assessed by a standard pre-MRI questionnaire.
29-1	5295-5304	Exclusion	_
29-2	5305-5313	criteria	_
29-3	5314-5322	included	_
29-4	5323-5324	1	_
29-5	5325-5326	)	_
29-6	5327-5334	current	_
29-7	5335-5338	use	_
29-8	5339-5341	of	_
29-9	5342-5349	regular	_
29-10	5350-5362	prescription	_
29-11	5363-5365	or	_
29-12	5366-5382	non-prescription	_
29-13	5383-5393	medication	_
29-14	5394-5398	that	_
29-15	5399-5404	could	_
29-16	5405-5408	not	_
29-17	5409-5411	be	_
29-18	5412-5419	stopped	_
29-19	5420-5421	;	_
29-20	5422-5423	2	_
29-21	5424-5425	)	_
29-22	5426-5433	current	_
29-23	5434-5441	primary	_
29-24	5442-5446	axis	_
29-25	5447-5448	I	_
29-26	5449-5458	diagnosis	_
29-27	5459-5460	,	_
29-28	5461-5465	past	_
29-29	5466-5473	history	_
29-30	5474-5476	of	_
29-31	5477-5486	psychosis	_
29-32	5487-5488	(	_
29-33	5489-5495	unless	_
29-34	5496-5508	drug-induced	_
29-35	5509-5510	)	_
29-36	5511-5512	;	_
29-37	5513-5514	3	_
29-38	5515-5516	)	_
29-39	5517-5524	current	_
29-40	5525-5527	or	_
29-41	5528-5532	past	_
29-42	5533-5540	history	_
29-43	5541-5543	of	_
29-44	5544-5552	enduring	_
29-45	5553-5559	severe	_
29-46	5560-5566	mental	_
29-47	5567-5574	illness	_
29-48	5575-5576	(	_
29-49	5577-5581	e.g.	_
29-50	5582-5583	,	_
29-51	5584-5597	schizophrenia	_
29-52	5598-5599	,	_
29-53	5600-5607	bipolar	_
29-54	5608-5617	affective	_
29-55	5618-5626	disorder	_
29-56	5627-5628	)	_
29-57	5629-5630	;	_
29-58	5631-5632	4	_
29-59	5633-5634	)	_
29-60	5635-5640	other	_
29-61	5641-5648	current	_
29-62	5649-5651	or	_
29-63	5652-5656	past	_
29-64	5657-5668	psychiatric	_
29-65	5669-5676	history	_
29-66	5677-5681	that	_
29-67	5682-5683	,	_
29-68	5684-5686	in	_
29-69	5687-5690	the	_
29-70	5691-5698	opinion	_
29-71	5699-5701	of	_
29-72	5702-5703	a	_
29-73	5704-5716	psychiatrist	_
29-74	5717-5718	,	_
29-75	5719-5734	contraindicated	_
29-76	5735-5748	participation	_
29-77	5749-5750	;	_
29-78	5751-5752	5	_
29-79	5753-5754	)	_
29-80	5755-5762	history	_
29-81	5763-5765	or	_
29-82	5766-5774	presence	_
29-83	5775-5777	of	_
29-84	5778-5779	a	_
29-85	5780-5791	significant	_
29-86	5792-5804	neurological	_
29-87	5805-5814	diagnosis	_
29-88	5815-5819	that	_
29-89	5820-5823	may	_
29-90	5824-5828	have	_
29-91	5829-5839	influenced	_
29-92	5840-5843	the	_
29-93	5844-5851	outcome	_
29-94	5852-5854	or	_
29-95	5855-5863	analysis	_
29-96	5864-5866	of	_
29-97	5867-5870	the	_
29-98	5871-5878	results	_
29-99	5879-5880	;	_
29-100	5881-5882	6	_
29-101	5883-5884	)	_
29-102	5885-5899	claustrophobia	_
29-103	5900-5902	or	_
29-104	5903-5909	unable	_
29-105	5910-5912	to	_
29-106	5913-5916	lie	_
29-107	5917-5922	still	_
29-108	5923-5925	in	_
29-109	5926-5929	the	_
29-110	5930-5933	MRI	_
29-111	5934-5941	scanner	_
29-112	5942-5945	for	_
29-113	5946-5948	up	_
29-114	5949-5951	to	_
29-115	5952-5954	90	_
29-116	5955-5958	min	_
29-117	5959-5962	and	_
29-118	5963-5964	7	_
29-119	5965-5966	)	_
29-120	5967-5975	presence	_
29-121	5976-5978	of	_
29-122	5979-5980	a	_
29-123	5981-5988	cardiac	_
29-124	5989-5998	pacemaker	_
29-125	5999-6000	,	_
29-126	6001-6006	other	_
29-127	6007-6017	electronic	_
29-128	6018-6024	device	_
29-129	6025-6027	or	_
29-130	6028-6033	other	_
29-131	6034-6037	MRI	_
29-132	6038-6054	contraindication	_
29-133	6055-6056	,	_
29-134	6057-6066	including	_
29-135	6067-6076	pregnancy	_
29-136	6077-6078	,	_
29-137	6079-6081	as	_
29-138	6082-6090	assessed	_
29-139	6091-6093	by	_
29-140	6094-6095	a	_
29-141	6096-6104	standard	_
29-142	6105-6112	pre-MRI	_
29-143	6113-6126	questionnaire	_
29-144	6127-6128	.	_

Text=Secondary or lifetime history of depression or anxiety was permitted in both the ADD and CON groups since these are very common psychiatric disorders.
30-1	6129-6138	Secondary	_
30-2	6139-6141	or	_
30-3	6142-6150	lifetime	_
30-4	6151-6158	history	_
30-5	6159-6161	of	_
30-6	6162-6172	depression	_
30-7	6173-6175	or	_
30-8	6176-6183	anxiety	_
30-9	6184-6187	was	_
30-10	6188-6197	permitted	_
30-11	6198-6200	in	_
30-12	6201-6205	both	_
30-13	6206-6209	the	_
30-14	6210-6213	ADD	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
30-15	6214-6217	and	_
30-16	6218-6221	CON	http://maven.renci.org/NeuroBridge/neurobridge#Continuous
30-17	6222-6228	groups	_
30-18	6229-6234	since	_
30-19	6235-6240	these	_
30-20	6241-6244	are	_
30-21	6245-6249	very	_
30-22	6250-6256	common	_
30-23	6257-6268	psychiatric	_
30-24	6269-6278	disorders	_
30-25	6279-6280	.	_

Text=All participants provided written informed consent.
31-1	6281-6284	All	_
31-2	6285-6297	participants	_
31-3	6298-6306	provided	_
31-4	6307-6314	written	_
31-5	6315-6323	informed	_
31-6	6324-6331	consent	_
31-7	6332-6333	.	_

Text=The study was conducted in accordance with the Declaration of Helsinki.
32-1	6334-6337	The	_
32-2	6338-6343	study	_
32-3	6344-6347	was	_
32-4	6348-6357	conducted	_
32-5	6358-6360	in	_
32-6	6361-6371	accordance	_
32-7	6372-6376	with	_
32-8	6377-6380	the	_
32-9	6381-6392	Declaration	_
32-10	6393-6395	of	_
32-11	6396-6404	Helsinki	_
32-12	6405-6406	.	_

Text=Ethical approval was obtained from West London and Gene Therapy Advisory Committee National Research Ethics Service Committee (11/H0707/9) and relevant research governance and Participant Identification Centre (PIC) approvals obtained.
33-1	6407-6414	Ethical	_
33-2	6415-6423	approval	_
33-3	6424-6427	was	_
33-4	6428-6436	obtained	_
33-5	6437-6441	from	_
33-6	6442-6446	West	_
33-7	6447-6453	London	_
33-8	6454-6457	and	_
33-9	6458-6462	Gene	_
33-10	6463-6470	Therapy	_
33-11	6471-6479	Advisory	_
33-12	6480-6489	Committee	_
33-13	6490-6498	National	_
33-14	6499-6507	Research	_
33-15	6508-6514	Ethics	_
33-16	6515-6522	Service	_
33-17	6523-6532	Committee	_
33-18	6533-6534	(	_
33-19	6535-6545	11/H0707/9	_
33-20	6546-6547	)	_
33-21	6548-6551	and	_
33-22	6552-6560	relevant	_
33-23	6561-6569	research	_
33-24	6570-6580	governance	_
33-25	6581-6584	and	_
33-26	6585-6596	Participant	_
33-27	6597-6611	Identification	_
33-28	6612-6618	Centre	_
33-29	6619-6620	(	_
33-30	6621-6624	PIC	_
33-31	6625-6626	)	_
33-32	6627-6636	approvals	_
33-33	6637-6645	obtained	_
33-34	6646-6647	.	_

Text=Monetary incentive delay task (MID) We used a “ monetary incentive delay task ” (MID), which was based on that originally employed by Knutson, and which we have used to already publish data from the ICCAM platform.
34-1	6648-6656	Monetary	http://maven.renci.org/NeuroBridge/neurobridge#MismatchNegativityTask
34-2	6657-6666	incentive	http://maven.renci.org/NeuroBridge/neurobridge#MismatchNegativityTask
34-3	6667-6672	delay	http://maven.renci.org/NeuroBridge/neurobridge#MismatchNegativityTask
34-4	6673-6677	task	http://maven.renci.org/NeuroBridge/neurobridge#MismatchNegativityTask
34-5	6678-6679	(	http://maven.renci.org/NeuroBridge/neurobridge#MismatchNegativityTask
34-6	6680-6683	MID	http://maven.renci.org/NeuroBridge/neurobridge#MismatchNegativityTask
34-7	6684-6685	)	http://maven.renci.org/NeuroBridge/neurobridge#MismatchNegativityTask
34-8	6686-6688	We	_
34-9	6689-6693	used	_
34-10	6694-6695	a	_
34-11	6696-6697	“	_
34-12	6698-6706	monetary	http://maven.renci.org/NeuroBridge/neurobridge#MismatchNegativityTask
34-13	6707-6716	incentive	http://maven.renci.org/NeuroBridge/neurobridge#MismatchNegativityTask
34-14	6717-6722	delay	http://maven.renci.org/NeuroBridge/neurobridge#MismatchNegativityTask
34-15	6723-6727	task	http://maven.renci.org/NeuroBridge/neurobridge#MismatchNegativityTask
34-16	6728-6729	”	http://maven.renci.org/NeuroBridge/neurobridge#MismatchNegativityTask
34-17	6730-6731	(	http://maven.renci.org/NeuroBridge/neurobridge#MismatchNegativityTask
34-18	6732-6735	MID	http://maven.renci.org/NeuroBridge/neurobridge#MismatchNegativityTask
34-19	6736-6737	)	http://maven.renci.org/NeuroBridge/neurobridge#MismatchNegativityTask
34-20	6738-6739	,	_
34-21	6740-6745	which	_
34-22	6746-6749	was	_
34-23	6750-6755	based	_
34-24	6756-6758	on	_
34-25	6759-6763	that	_
34-26	6764-6774	originally	_
34-27	6775-6783	employed	_
34-28	6784-6786	by	_
34-29	6787-6794	Knutson	_
34-30	6795-6796	,	_
34-31	6797-6800	and	_
34-32	6801-6806	which	_
34-33	6807-6809	we	_
34-34	6810-6814	have	_
34-35	6815-6819	used	_
34-36	6820-6822	to	_
34-37	6823-6830	already	_
34-38	6831-6838	publish	_
34-39	6839-6843	data	_
34-40	6844-6848	from	_
34-41	6849-6852	the	_
34-42	6853-6858	ICCAM	_
34-43	6859-6867	platform	_
34-44	6868-6869	.	_

Text=At the beginning of each trial, participants viewed one of three symbols (a cue) that indicated the potential to gain fifty pence (square containing an ascending arrow), lose fifty pence (square containing a descending arrow) or experience no financial outcome (square containing a horizontal line - here referred to as a neutral trial).
35-1	6870-6872	At	_
35-2	6873-6876	the	_
35-3	6877-6886	beginning	_
35-4	6887-6889	of	_
35-5	6890-6894	each	_
35-6	6895-6900	trial	_
35-7	6901-6902	,	_
35-8	6903-6915	participants	_
35-9	6916-6922	viewed	_
35-10	6923-6926	one	_
35-11	6927-6929	of	_
35-12	6930-6935	three	_
35-13	6936-6943	symbols	_
35-14	6944-6945	(	_
35-15	6946-6947	a	_
35-16	6948-6951	cue	_
35-17	6952-6953	)	_
35-18	6954-6958	that	_
35-19	6959-6968	indicated	_
35-20	6969-6972	the	_
35-21	6973-6982	potential	_
35-22	6983-6985	to	_
35-23	6986-6990	gain	_
35-24	6991-6996	fifty	_
35-25	6997-7002	pence	_
35-26	7003-7004	(	_
35-27	7005-7011	square	_
35-28	7012-7022	containing	_
35-29	7023-7025	an	_
35-30	7026-7035	ascending	_
35-31	7036-7041	arrow	_
35-32	7042-7043	)	_
35-33	7044-7045	,	_
35-34	7046-7050	lose	_
35-35	7051-7056	fifty	_
35-36	7057-7062	pence	_
35-37	7063-7064	(	_
35-38	7065-7071	square	_
35-39	7072-7082	containing	_
35-40	7083-7084	a	_
35-41	7085-7095	descending	_
35-42	7096-7101	arrow	_
35-43	7102-7103	)	_
35-44	7104-7106	or	_
35-45	7107-7117	experience	_
35-46	7118-7120	no	_
35-47	7121-7130	financial	_
35-48	7131-7138	outcome	_
35-49	7139-7140	(	_
35-50	7141-7147	square	_
35-51	7148-7158	containing	_
35-52	7159-7160	a	_
35-53	7161-7171	horizontal	_
35-54	7172-7176	line	_
35-55	7177-7178	-	_
35-56	7179-7183	here	_
35-57	7184-7192	referred	_
35-58	7193-7195	to	_
35-59	7196-7198	as	_
35-60	7199-7200	a	_
35-61	7201-7208	neutral	_
35-62	7209-7214	trial	_
35-63	7215-7216	)	_
35-64	7217-7218	.	_

Text=Each cue was presented for one second, with a variable duration (2–4 s) for the subsequent anticipation period.
36-1	7219-7223	Each	_
36-2	7224-7227	cue	_
36-3	7228-7231	was	_
36-4	7232-7241	presented	_
36-5	7242-7245	for	_
36-6	7246-7249	one	_
36-7	7250-7256	second	_
36-8	7257-7258	,	_
36-9	7259-7263	with	_
36-10	7264-7265	a	_
36-11	7266-7274	variable	_
36-12	7275-7283	duration	_
36-13	7284-7285	(	_
36-14	7286-7289	2–4	_
36-15	7290-7291	s	_
36-16	7292-7293	)	_
36-17	7294-7297	for	_
36-18	7298-7301	the	_
36-19	7302-7312	subsequent	_
36-20	7313-7325	anticipation	_
36-21	7326-7332	period	_
36-22	7333-7334	.	_

Text=Following the anticipation period, participants made a button press response upon the presentation of a visual target (star located within a circle).
37-1	7335-7344	Following	_
37-2	7345-7348	the	_
37-3	7349-7361	anticipation	_
37-4	7362-7368	period	_
37-5	7369-7370	,	_
37-6	7371-7383	participants	_
37-7	7384-7388	made	_
37-8	7389-7390	a	_
37-9	7391-7397	button	_
37-10	7398-7403	press	_
37-11	7404-7412	response	_
37-12	7413-7417	upon	_
37-13	7418-7421	the	_
37-14	7422-7434	presentation	_
37-15	7435-7437	of	_
37-16	7438-7439	a	_
37-17	7440-7446	visual	_
37-18	7447-7453	target	_
37-19	7454-7455	(	_
37-20	7456-7460	star	_
37-21	7461-7468	located	_
37-22	7469-7475	within	_
37-23	7476-7477	a	_
37-24	7478-7484	circle	_
37-25	7485-7486	)	_
37-26	7487-7488	.	_

Text=Following their response to the visual target, participants received feedback (1.5 s) as to whether they were successful (“ Hit ”) or unsuccessful (“ Miss ”) on that trial and saw a running total of their winnings up to that point in the task.
38-1	7489-7498	Following	_
38-2	7499-7504	their	_
38-3	7505-7513	response	_
38-4	7514-7516	to	_
38-5	7517-7520	the	_
38-6	7521-7527	visual	_
38-7	7528-7534	target	_
38-8	7535-7536	,	_
38-9	7537-7549	participants	_
38-10	7550-7558	received	_
38-11	7559-7567	feedback	_
38-12	7568-7569	(	_
38-13	7570-7573	1.5	_
38-14	7574-7575	s	_
38-15	7576-7577	)	_
38-16	7578-7580	as	_
38-17	7581-7583	to	_
38-18	7584-7591	whether	_
38-19	7592-7596	they	_
38-20	7597-7601	were	_
38-21	7602-7612	successful	_
38-22	7613-7614	(	_
38-23	7615-7616	“	_
38-24	7617-7620	Hit	_
38-25	7621-7622	”	_
38-26	7623-7624	)	_
38-27	7625-7627	or	_
38-28	7628-7640	unsuccessful	_
38-29	7641-7642	(	_
38-30	7643-7644	“	_
38-31	7645-7649	Miss	_
38-32	7650-7651	”	_
38-33	7652-7653	)	_
38-34	7654-7656	on	_
38-35	7657-7661	that	_
38-36	7662-7667	trial	_
38-37	7668-7671	and	_
38-38	7672-7675	saw	_
38-39	7676-7677	a	_
38-40	7678-7685	running	_
38-41	7686-7691	total	_
38-42	7692-7694	of	_
38-43	7695-7700	their	_
38-44	7701-7709	winnings	_
38-45	7710-7712	up	_
38-46	7713-7715	to	_
38-47	7716-7720	that	_
38-48	7721-7726	point	_
38-49	7727-7729	in	_
38-50	7730-7733	the	_
38-51	7734-7738	task	_
38-52	7739-7740	.	_

Text=Following feedback, there was an end fixation period (3–5 s) before the commencement of the next trial.
39-1	7741-7750	Following	_
39-2	7751-7759	feedback	_
39-3	7760-7761	,	_
39-4	7762-7767	there	_
39-5	7768-7771	was	_
39-6	7772-7774	an	_
39-7	7775-7778	end	_
39-8	7779-7787	fixation	_
39-9	7788-7794	period	_
39-10	7795-7796	(	_
39-11	7797-7800	3–5	_
39-12	7801-7802	s	_
39-13	7803-7804	)	_
39-14	7805-7811	before	_
39-15	7812-7815	the	_
39-16	7816-7828	commencement	_
39-17	7829-7831	of	_
39-18	7832-7835	the	_
39-19	7836-7840	next	_
39-20	7841-7846	trial	_
39-21	7847-7848	.	_

Text=Because the primary objective of ICCAM was to examine the neural correlates of reward anticipation, we chose to use a smaller number of loss trials in order to amplify the incentive salience of the gain trials during the task.
40-1	7849-7856	Because	_
40-2	7857-7860	the	_
40-3	7861-7868	primary	_
40-4	7869-7878	objective	_
40-5	7879-7881	of	_
40-6	7882-7887	ICCAM	_
40-7	7888-7891	was	_
40-8	7892-7894	to	_
40-9	7895-7902	examine	_
40-10	7903-7906	the	_
40-11	7907-7913	neural	_
40-12	7914-7924	correlates	_
40-13	7925-7927	of	_
40-14	7928-7934	reward	_
40-15	7935-7947	anticipation	_
40-16	7948-7949	,	_
40-17	7950-7952	we	_
40-18	7953-7958	chose	_
40-19	7959-7961	to	_
40-20	7962-7965	use	_
40-21	7966-7967	a	_
40-22	7968-7975	smaller	_
40-23	7976-7982	number	_
40-24	7983-7985	of	_
40-25	7986-7990	loss	_
40-26	7991-7997	trials	_
40-27	7998-8000	in	_
40-28	8001-8006	order	_
40-29	8007-8009	to	_
40-30	8010-8017	amplify	_
40-31	8018-8021	the	_
40-32	8022-8031	incentive	_
40-33	8032-8040	salience	_
40-34	8041-8043	of	_
40-35	8044-8047	the	_
40-36	8048-8052	gain	_
40-37	8053-8059	trials	_
40-38	8060-8066	during	_
40-39	8067-8070	the	_
40-40	8071-8075	task	_
40-41	8076-8077	.	_

Text=Consequently, there was a total of 18 gain, 6 lose and 18 neutral trials on each run of the task.
41-1	8078-8090	Consequently	_
41-2	8091-8092	,	_
41-3	8093-8098	there	_
41-4	8099-8102	was	_
41-5	8103-8104	a	_
41-6	8105-8110	total	_
41-7	8111-8113	of	_
41-8	8114-8116	18	_
41-9	8117-8121	gain	_
41-10	8122-8123	,	_
41-11	8124-8125	6	_
41-12	8126-8130	lose	_
41-13	8131-8134	and	_
41-14	8135-8137	18	_
41-15	8138-8145	neutral	_
41-16	8146-8152	trials	_
41-17	8153-8155	on	_
41-18	8156-8160	each	_
41-19	8161-8164	run	_
41-20	8165-8167	of	_
41-21	8168-8171	the	_
41-22	8172-8176	task	_
41-23	8177-8178	.	_

Text=The MID task was tailored to adapt to the visual target reaction time of each participant by using a staircase algorithm, such that the presentation of the visual target became shorter as performance improved during the experiment.
42-1	8179-8182	The	_
42-2	8183-8186	MID	_
42-3	8187-8191	task	_
42-4	8192-8195	was	_
42-5	8196-8204	tailored	_
42-6	8205-8207	to	_
42-7	8208-8213	adapt	_
42-8	8214-8216	to	_
42-9	8217-8220	the	_
42-10	8221-8227	visual	_
42-11	8228-8234	target	_
42-12	8235-8243	reaction	_
42-13	8244-8248	time	_
42-14	8249-8251	of	_
42-15	8252-8256	each	_
42-16	8257-8268	participant	_
42-17	8269-8271	by	_
42-18	8272-8277	using	_
42-19	8278-8279	a	_
42-20	8280-8289	staircase	_
42-21	8290-8299	algorithm	_
42-22	8300-8301	,	_
42-23	8302-8306	such	_
42-24	8307-8311	that	_
42-25	8312-8315	the	_
42-26	8316-8328	presentation	_
42-27	8329-8331	of	_
42-28	8332-8335	the	_
42-29	8336-8342	visual	_
42-30	8343-8349	target	_
42-31	8350-8356	became	_
42-32	8357-8364	shorter	_
42-33	8365-8367	as	_
42-34	8368-8379	performance	_
42-35	8380-8388	improved	_
42-36	8389-8395	during	_
42-37	8396-8399	the	_
42-38	8400-8410	experiment	_
42-39	8411-8412	.	_

Text=This enabled us to set a limit on the success rate of each participant (∼66%), which additionally served to incentivize participants to engage in the task.
43-1	8413-8417	This	_
43-2	8418-8425	enabled	_
43-3	8426-8428	us	_
43-4	8429-8431	to	_
43-5	8432-8435	set	_
43-6	8436-8437	a	_
43-7	8438-8443	limit	_
43-8	8444-8446	on	_
43-9	8447-8450	the	_
43-10	8451-8458	success	_
43-11	8459-8463	rate	_
43-12	8464-8466	of	_
43-13	8467-8471	each	_
43-14	8472-8483	participant	_
43-15	8484-8485	(	_
43-16	8486-8489	∼66	_
43-17	8490-8491	%	_
43-18	8492-8493	)	_
43-19	8494-8495	,	_
43-20	8496-8501	which	_
43-21	8502-8514	additionally	_
43-22	8515-8521	served	_
43-23	8522-8524	to	_
43-24	8525-8536	incentivize	_
43-25	8537-8549	participants	_
43-26	8550-8552	to	_
43-27	8553-8559	engage	_
43-28	8560-8562	in	_
43-29	8563-8566	the	_
43-30	8567-8571	task	_
43-31	8572-8573	.	_

Text=Participants were instructed to maximize their winnings and were told they would receive them at the end of the study.
44-1	8574-8586	Participants	_
44-2	8587-8591	were	_
44-3	8592-8602	instructed	_
44-4	8603-8605	to	_
44-5	8606-8614	maximize	_
44-6	8615-8620	their	_
44-7	8621-8629	winnings	_
44-8	8630-8633	and	_
44-9	8634-8638	were	_
44-10	8639-8643	told	_
44-11	8644-8648	they	_
44-12	8649-8654	would	_
44-13	8655-8662	receive	_
44-14	8663-8667	them	_
44-15	8668-8670	at	_
44-16	8671-8674	the	_
44-17	8675-8678	end	_
44-18	8679-8681	of	_
44-19	8682-8685	the	_
44-20	8686-8691	study	_
44-21	8692-8693	.	_

Text=Dependent measures were accuracy (percentage) and mean reaction time (milliseconds) to the visual target on each of the gain, lose and neutral trials, and the amount won (£) on the task.
45-1	8694-8703	Dependent	_
45-2	8704-8712	measures	_
45-3	8713-8717	were	_
45-4	8718-8726	accuracy	_
45-5	8727-8728	(	_
45-6	8729-8739	percentage	_
45-7	8740-8741	)	_
45-8	8742-8745	and	_
45-9	8746-8750	mean	_
45-10	8751-8759	reaction	_
45-11	8760-8764	time	_
45-12	8765-8766	(	_
45-13	8767-8779	milliseconds	_
45-14	8780-8781	)	_
45-15	8782-8784	to	_
45-16	8785-8788	the	_
45-17	8789-8795	visual	_
45-18	8796-8802	target	_
45-19	8803-8805	on	_
45-20	8806-8810	each	_
45-21	8811-8813	of	_
45-22	8814-8817	the	_
45-23	8818-8822	gain	_
45-24	8823-8824	,	_
45-25	8825-8829	lose	_
45-26	8830-8833	and	_
45-27	8834-8841	neutral	_
45-28	8842-8848	trials	_
45-29	8849-8850	,	_
45-30	8851-8854	and	_
45-31	8855-8858	the	_
45-32	8859-8865	amount	_
45-33	8866-8869	won	_
45-34	8870-8871	(	_
45-35	8872-8873	£	_
45-36	8874-8875	)	_
45-37	8876-8878	on	_
45-38	8879-8882	the	_
45-39	8883-8887	task	_
45-40	8888-8889	.	_

Text=Participants completed two runs of the task (432 s each) during scanning.
46-1	8890-8902	Participants	_
46-2	8903-8912	completed	_
46-3	8913-8916	two	_
46-4	8917-8921	runs	_
46-5	8922-8924	of	_
46-6	8925-8928	the	_
46-7	8929-8933	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
46-8	8934-8935	(	_
46-9	8936-8939	432	_
46-10	8940-8941	s	_
46-11	8942-8946	each	_
46-12	8947-8948	)	_
46-13	8949-8955	during	_
46-14	8956-8964	scanning	_
46-15	8965-8966	.	_

Text=The task was programmed using E-Prime version 2.0 (Psychology Software Tools, Pittsburgh, USA).
47-1	8967-8970	The	_
47-2	8971-8975	task	_
47-3	8976-8979	was	_
47-4	8980-8990	programmed	_
47-5	8991-8996	using	_
47-6	8997-9004	E-Prime	_
47-7	9005-9012	version	_
47-8	9013-9016	2.0	_
47-9	9017-9018	(	_
47-10	9019-9029	Psychology	_
47-11	9030-9038	Software	_
47-12	9039-9044	Tools	_
47-13	9045-9046	,	_
47-14	9047-9057	Pittsburgh	_
47-15	9058-9059	,	_
47-16	9060-9063	USA	_
47-17	9064-9065	)	_
47-18	9066-9067	.	_

Text=Statistics Group demographics were compared using simple independent samples t-test analyses.
48-1	9068-9078	Statistics	_
48-2	9079-9084	Group	_
48-3	9085-9097	demographics	_
48-4	9098-9102	were	_
48-5	9103-9111	compared	_
48-6	9112-9117	using	_
48-7	9118-9124	simple	_
48-8	9125-9136	independent	_
48-9	9137-9144	samples	_
48-10	9145-9151	t-test	_
48-11	9152-9160	analyses	_
48-12	9161-9162	.	_

Text=For analyses conducted on MID performance, two (Group: CON vs. ADD) by two (Condition: Gain vs.
49-1	9163-9166	For	_
49-2	9167-9175	analyses	_
49-3	9176-9185	conducted	_
49-4	9186-9188	on	_
49-5	9189-9192	MID	_
49-6	9193-9204	performance	_
49-7	9205-9206	,	_
49-8	9207-9210	two	_
49-9	9211-9212	(	_
49-10	9213-9218	Group	_
49-11	9219-9220	:	_
49-12	9221-9224	CON	_
49-13	9225-9228	vs.	_
49-14	9229-9232	ADD	_
49-15	9233-9234	)	_
49-16	9235-9237	by	_
49-17	9238-9241	two	_
49-18	9242-9243	(	_
49-19	9244-9253	Condition	_
49-20	9254-9255	:	_
49-21	9256-9260	Gain	_
49-22	9261-9263	vs	_
49-23	9264-9265	.	_

Text=Neutral) analyses of variance were conducted.
50-1	9266-9273	Neutral	_
50-2	9274-9275	)	_
50-3	9276-9284	analyses	_
50-4	9285-9287	of	_
50-5	9288-9296	variance	_
50-6	9297-9301	were	_
50-7	9302-9311	conducted	_
50-8	9312-9313	.	_

Text=The CON and ADD groups were also compared on the lose accuracy and lose reaction time performance measures, as well as the amount of money won (£), using analyses of variance.
51-1	9314-9317	The	_
51-2	9318-9321	CON	_
51-3	9322-9325	and	_
51-4	9326-9329	ADD	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
51-5	9330-9336	groups	_
51-6	9337-9341	were	_
51-7	9342-9346	also	_
51-8	9347-9355	compared	_
51-9	9356-9358	on	_
51-10	9359-9362	the	_
51-11	9363-9367	lose	_
51-12	9368-9376	accuracy	_
51-13	9377-9380	and	_
51-14	9381-9385	lose	_
51-15	9386-9394	reaction	_
51-16	9395-9399	time	_
51-17	9400-9411	performance	_
51-18	9412-9420	measures	_
51-19	9421-9422	,	_
51-20	9423-9425	as	_
51-21	9426-9430	well	_
51-22	9431-9433	as	_
51-23	9434-9437	the	_
51-24	9438-9444	amount	_
51-25	9445-9447	of	_
51-26	9448-9453	money	_
51-27	9454-9457	won	_
51-28	9458-9459	(	_
51-29	9460-9461	£	_
51-30	9462-9463	)	_
51-31	9464-9465	,	_
51-32	9466-9471	using	_
51-33	9472-9480	analyses	_
51-34	9481-9483	of	_
51-35	9484-9492	variance	_
51-36	9493-9494	.	_

Text=These analyses were conducted controlling for study site.
52-1	9495-9500	These	_
52-2	9501-9509	analyses	_
52-3	9510-9514	were	_
52-4	9515-9524	conducted	_
52-5	9525-9536	controlling	_
52-6	9537-9540	for	_
52-7	9541-9546	study	_
52-8	9547-9551	site	_
52-9	9552-9553	.	_

Text=For the graph measures (see below) we conducted two (Group: CON vs. ADD) by five (1 ⩽ K ⩽ 5) analyses of variance, while also controlling for study site.
53-1	9554-9557	For	_
53-2	9558-9561	the	_
53-3	9562-9567	graph	_
53-4	9568-9576	measures	_
53-5	9577-9578	(	_
53-6	9579-9582	see	_
53-7	9583-9588	below	_
53-8	9589-9590	)	_
53-9	9591-9593	we	_
53-10	9594-9603	conducted	_
53-11	9604-9607	two	_
53-12	9608-9609	(	_
53-13	9610-9615	Group	_
53-14	9616-9617	:	_
53-15	9618-9621	CON	_
53-16	9622-9625	vs.	_
53-17	9626-9629	ADD	_
53-18	9630-9631	)	_
53-19	9632-9634	by	_
53-20	9635-9639	five	_
53-21	9640-9641	(	_
53-22	9642-9643	1	_
53-23	9644-9645	⩽	_
53-24	9646-9647	K	_
53-25	9648-9649	⩽	_
53-26	9650-9651	5	_
53-27	9652-9653	)	_
53-28	9654-9662	analyses	_
53-29	9663-9665	of	_
53-30	9666-9674	variance	_
53-31	9675-9676	,	_
53-32	9677-9682	while	_
53-33	9683-9687	also	_
53-34	9688-9699	controlling	_
53-35	9700-9703	for	_
53-36	9704-9709	study	_
53-37	9710-9714	site	_
53-38	9715-9716	.	_

Text=All these analyses were conducted using permutation testing (5000 iterations) in the R statistical software package (www.R-project.org).
54-1	9717-9720	All	_
54-2	9721-9726	these	_
54-3	9727-9735	analyses	_
54-4	9736-9740	were	_
54-5	9741-9750	conducted	_
54-6	9751-9756	using	_
54-7	9757-9768	permutation	_
54-8	9769-9776	testing	_
54-9	9777-9778	(	_
54-10	9779-9783	5000	_
54-11	9784-9794	iterations	_
54-12	9795-9796	)	_
54-13	9797-9799	in	_
54-14	9800-9803	the	_
54-15	9804-9805	R	_
54-16	9806-9817	statistical	_
54-17	9818-9826	software	_
54-18	9827-9834	package	_
54-19	9835-9836	(	_
54-20	9837-9854	www.R-project.org	_
54-21	9855-9856	)	_
54-22	9857-9858	.	_

Text=Functional MRI (fMRI) Data acquisition The ICCAM platform was designed to allow the rapid testing across sites of multiple compounds relevant to addiction treatment.
55-1	9859-9869	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
55-2	9870-9873	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
55-3	9874-9875	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
55-4	9876-9880	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
55-5	9881-9882	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
55-6	9883-9887	Data	_
55-7	9888-9899	acquisition	_
55-8	9900-9903	The	_
55-9	9904-9909	ICCAM	_
55-10	9910-9918	platform	_
55-11	9919-9922	was	_
55-12	9923-9931	designed	_
55-13	9932-9934	to	_
55-14	9935-9940	allow	_
55-15	9941-9944	the	_
55-16	9945-9950	rapid	_
55-17	9951-9958	testing	_
55-18	9959-9965	across	_
55-19	9966-9971	sites	_
55-20	9972-9974	of	_
55-21	9975-9983	multiple	_
55-22	9984-9993	compounds	_
55-23	9994-10002	relevant	_
55-24	10003-10005	to	_
55-25	10006-10015	addiction	_
55-26	10016-10025	treatment	_
55-27	10026-10027	.	_

Text=Imaging at multiple sites in parallel on the ICCAM platform accelerated study completion, through the sharing of expertise, infrastructure and capacity.
56-1	10028-10035	Imaging	_
56-2	10036-10038	at	_
56-3	10039-10047	multiple	_
56-4	10048-10053	sites	_
56-5	10054-10056	in	_
56-6	10057-10065	parallel	_
56-7	10066-10068	on	_
56-8	10069-10072	the	_
56-9	10073-10078	ICCAM	_
56-10	10079-10087	platform	_
56-11	10088-10099	accelerated	_
56-12	10100-10105	study	_
56-13	10106-10116	completion	_
56-14	10117-10118	,	_
56-15	10119-10126	through	_
56-16	10127-10130	the	_
56-17	10131-10138	sharing	_
56-18	10139-10141	of	_
56-19	10142-10151	expertise	_
56-20	10152-10153	,	_
56-21	10154-10168	infrastructure	_
56-22	10169-10172	and	_
56-23	10173-10181	capacity	_
56-24	10182-10183	.	_

Text=For a more comprehensive description of data acquisition across the three sites on ICCAM, please see McGonigle et al.
57-1	10184-10187	For	_
57-2	10188-10189	a	_
57-3	10190-10194	more	_
57-4	10195-10208	comprehensive	_
57-5	10209-10220	description	_
57-6	10221-10223	of	_
57-7	10224-10228	data	_
57-8	10229-10240	acquisition	_
57-9	10241-10247	across	_
57-10	10248-10251	the	_
57-11	10252-10257	three	_
57-12	10258-10263	sites	_
57-13	10264-10266	on	_
57-14	10267-10272	ICCAM	_
57-15	10273-10274	,	_
57-16	10275-10281	please	_
57-17	10282-10285	see	_
57-18	10286-10295	McGonigle	_
57-19	10296-10298	et	_
57-20	10299-10301	al	_
57-21	10302-10303	.	_

Text=Briefly, all centres operated MRI machines with a main magnetic field of 3 T (T).
58-1	10304-10311	Briefly	_
58-2	10312-10313	,	_
58-3	10314-10317	all	_
58-4	10318-10325	centres	_
58-5	10326-10334	operated	_
58-6	10335-10338	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
58-7	10339-10347	machines	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
58-8	10348-10352	with	_
58-9	10353-10354	a	_
58-10	10355-10359	main	_
58-11	10360-10368	magnetic	_
58-12	10369-10374	field	_
58-13	10375-10377	of	_
58-14	10378-10379	3	_
58-15	10380-10381	T	_
58-16	10382-10383	(	_
58-17	10384-10385	T	_
58-18	10386-10387	)	_
58-19	10388-10389	.	_

Text=Centres in London and Cambridge operated nominally identical 3 T Siemens Tim Trio systems running the syngo MR B17 software with a Siemens 32 channel receive-only phased-array head coil.
59-1	10390-10397	Centres	_
59-2	10398-10400	in	_
59-3	10401-10407	London	_
59-4	10408-10411	and	_
59-5	10412-10421	Cambridge	_
59-6	10422-10430	operated	_
59-7	10431-10440	nominally	_
59-8	10441-10450	identical	_
59-9	10451-10452	3	_
59-10	10453-10454	T	_
59-11	10455-10462	Siemens	_
59-12	10463-10466	Tim	_
59-13	10467-10471	Trio	_
59-14	10472-10479	systems	_
59-15	10480-10487	running	_
59-16	10488-10491	the	_
59-17	10492-10497	syngo	_
59-18	10498-10500	MR	_
59-19	10501-10504	B17	_
59-20	10505-10513	software	_
59-21	10514-10518	with	_
59-22	10519-10520	a	_
59-23	10521-10528	Siemens	_
59-24	10529-10531	32	_
59-25	10532-10539	channel	_
59-26	10540-10552	receive-only	_
59-27	10553-10565	phased-array	_
59-28	10566-10570	head	_
59-29	10571-10575	coil	_
59-30	10576-10577	.	_

Text=The Manchester centre operated a 3 T Philips Achieva running version 2.6.3.5 software and an 8 element SENSE head coil.
60-1	10578-10581	The	_
60-2	10582-10592	Manchester	_
60-3	10593-10599	centre	_
60-4	10600-10608	operated	_
60-5	10609-10610	a	_
60-6	10611-10612	3	_
60-7	10613-10614	T	_
60-8	10615-10622	Philips	_
60-9	10623-10630	Achieva	_
60-10	10631-10638	running	_
60-11	10639-10646	version	_
60-12	10647-10654	2.6.3.5	_
60-13	10655-10663	software	_
60-14	10664-10667	and	_
60-15	10668-10670	an	_
60-16	10671-10672	8	_
60-17	10673-10680	element	_
60-18	10681-10686	SENSE	_
60-19	10687-10691	head	_
60-20	10692-10696	coil	_
60-21	10697-10698	.	_

Text=For anatomical images, 160 high-resolution T1-weighted anatomic MPRAGE axial images (FOV 256 mm, thickness 1.0 mm, voxel size 1.0 × 1.0 × 1.0) were acquired (total duration 303 s).
61-1	10699-10702	For	_
61-2	10703-10713	anatomical	_
61-3	10714-10720	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
61-4	10721-10722	,	_
61-5	10723-10726	160	_
61-6	10727-10742	high-resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
61-7	10743-10754	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
61-8	10755-10763	anatomic	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
61-9	10764-10770	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
61-10	10771-10776	axial	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
61-11	10777-10783	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
61-12	10784-10785	(	_
61-13	10786-10789	FOV	_
61-14	10790-10793	256	_
61-15	10794-10796	mm	_
61-16	10797-10798	,	_
61-17	10799-10808	thickness	_
61-18	10809-10812	1.0	_
61-19	10813-10815	mm	_
61-20	10816-10817	,	_
61-21	10818-10823	voxel	_
61-22	10824-10828	size	_
61-23	10829-10832	1.0	_
61-24	10833-10834	×	_
61-25	10835-10838	1.0	_
61-26	10839-10840	×	_
61-27	10841-10844	1.0	_
61-28	10845-10846	)	_
61-29	10847-10851	were	_
61-30	10852-10860	acquired	_
61-31	10861-10862	(	_
61-32	10863-10868	total	_
61-33	10869-10877	duration	_
61-34	10878-10881	303	_
61-35	10882-10883	s	_
61-36	10884-10885	)	_
61-37	10886-10887	.	_

Text=Functional data were acquired using a T2 * weighted echo-planar imaging sequence collecting 36 non-contiguous (0% gap) 3.0 mm axial slices covering the entire brain (TE = 31 ms, TR = 2000 ms, FOV 225 mm, 64 × 64 mm matrix size in Fourier space).
62-1	10888-10898	Functional	_
62-2	10899-10903	data	_
62-3	10904-10908	were	_
62-4	10909-10917	acquired	_
62-5	10918-10923	using	_
62-6	10924-10925	a	_
62-7	10926-10928	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
62-8	10929-10930	*	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
62-9	10931-10939	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
62-10	10940-10951	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
62-11	10952-10959	imaging	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
62-12	10960-10968	sequence	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
62-13	10969-10979	collecting	_
62-14	10980-10982	36	_
62-15	10983-10997	non-contiguous	_
62-16	10998-10999	(	_
62-17	11000-11001	0	_
62-18	11002-11003	%	_
62-19	11004-11007	gap	_
62-20	11008-11009	)	_
62-21	11010-11013	3.0	_
62-22	11014-11016	mm	_
62-23	11017-11022	axial	_
62-24	11023-11029	slices	_
62-25	11030-11038	covering	_
62-26	11039-11042	the	_
62-27	11043-11049	entire	_
62-28	11050-11055	brain	_
62-29	11056-11057	(	_
62-30	11058-11060	TE	_
62-31	11061-11062	=	_
62-32	11063-11065	31	_
62-33	11066-11068	ms	_
62-34	11069-11070	,	_
62-35	11071-11073	TR	_
62-36	11074-11075	=	_
62-37	11076-11080	2000	_
62-38	11081-11083	ms	_
62-39	11084-11085	,	_
62-40	11086-11089	FOV	_
62-41	11090-11093	225	_
62-42	11094-11096	mm	_
62-43	11097-11098	,	_
62-44	11099-11101	64	_
62-45	11102-11103	×	_
62-46	11104-11106	64	_
62-47	11107-11109	mm	_
62-48	11110-11116	matrix	_
62-49	11117-11121	size	_
62-50	11122-11124	in	_
62-51	11125-11132	Fourier	_
62-52	11133-11138	space	_
62-53	11139-11140	)	_
62-54	11141-11142	.	_

Text=Each run of the MID task produced a total of 216 volumes of functional MRI data.
63-1	11143-11147	Each	_
63-2	11148-11151	run	_
63-3	11152-11154	of	_
63-4	11155-11158	the	_
63-5	11159-11162	MID	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
63-6	11163-11167	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
63-7	11168-11176	produced	_
63-8	11177-11178	a	_
63-9	11179-11184	total	_
63-10	11185-11187	of	_
63-11	11188-11191	216	_
63-12	11192-11199	volumes	_
63-13	11200-11202	of	_
63-14	11203-11213	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
63-15	11214-11217	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
63-16	11218-11222	data	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
63-17	11223-11224	.	_

Text=fMRI Data analyses Data pre-processing and statistical analysis were conducted using FEAT (fMRI Expert Analysis Tool) from the FMRIB Software Library (www.fmrib.ox.ac.uk/fsl).
64-1	11225-11229	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
64-2	11230-11234	Data	_
64-3	11235-11243	analyses	_
64-4	11244-11248	Data	_
64-5	11249-11263	pre-processing	_
64-6	11264-11267	and	_
64-7	11268-11279	statistical	_
64-8	11280-11288	analysis	_
64-9	11289-11293	were	_
64-10	11294-11303	conducted	_
64-11	11304-11309	using	_
64-12	11310-11314	FEAT	_
64-13	11315-11316	(	_
64-14	11317-11321	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
64-15	11322-11328	Expert	_
64-16	11329-11337	Analysis	_
64-17	11338-11342	Tool	_
64-18	11343-11344	)	_
64-19	11345-11349	from	_
64-20	11350-11353	the	_
64-21	11354-11359	FMRIB	_
64-22	11360-11368	Software	_
64-23	11369-11376	Library	_
64-24	11377-11378	(	_
64-25	11379-11401	www.fmrib.ox.ac.uk/fsl	_
64-26	11402-11403	)	_
64-27	11404-11405	.	_

Text=Pre-statistical processing was as follows: motion correction utilizing FMRIB ’ s Linear Image Registration Tool (MCFLIRT; non-brain matter removal using Brain Extraction Tool (BET); spatial smoothing with a 5-mm full-width half maximum Gaussian kernel; mean-based intensity normalization; nonlinear high-pass temporal filtering (Gaussian-weighted least squares straight line fit, with sigma = 25.0 s).
65-1	11406-11421	Pre-statistical	_
65-2	11422-11432	processing	_
65-3	11433-11436	was	_
65-4	11437-11439	as	_
65-5	11440-11447	follows	_
65-6	11448-11449	:	_
65-7	11450-11456	motion	_
65-8	11457-11467	correction	_
65-9	11468-11477	utilizing	_
65-10	11478-11483	FMRIB	_
65-11	11484-11485	’	_
65-12	11486-11487	s	_
65-13	11488-11494	Linear	_
65-14	11495-11500	Image	_
65-15	11501-11513	Registration	_
65-16	11514-11518	Tool	_
65-17	11519-11520	(	_
65-18	11521-11528	MCFLIRT	_
65-19	11529-11530	;	_
65-20	11531-11540	non-brain	_
65-21	11541-11547	matter	_
65-22	11548-11555	removal	_
65-23	11556-11561	using	_
65-24	11562-11567	Brain	_
65-25	11568-11578	Extraction	_
65-26	11579-11583	Tool	_
65-27	11584-11585	(	_
65-28	11586-11589	BET	_
65-29	11590-11591	)	_
65-30	11592-11593	;	_
65-31	11594-11601	spatial	_
65-32	11602-11611	smoothing	_
65-33	11612-11616	with	_
65-34	11617-11618	a	_
65-35	11619-11623	5-mm	_
65-36	11624-11634	full-width	_
65-37	11635-11639	half	_
65-38	11640-11647	maximum	_
65-39	11648-11656	Gaussian	_
65-40	11657-11663	kernel	_
65-41	11664-11665	;	_
65-42	11666-11676	mean-based	_
65-43	11677-11686	intensity	_
65-44	11687-11700	normalization	_
65-45	11701-11702	;	_
65-46	11703-11712	nonlinear	_
65-47	11713-11722	high-pass	_
65-48	11723-11731	temporal	_
65-49	11732-11741	filtering	_
65-50	11742-11743	(	_
65-51	11744-11761	Gaussian-weighted	_
65-52	11762-11767	least	_
65-53	11768-11775	squares	_
65-54	11776-11784	straight	_
65-55	11785-11789	line	_
65-56	11790-11793	fit	_
65-57	11794-11795	,	_
65-58	11796-11800	with	_
65-59	11801-11806	sigma	_
65-60	11807-11808	=	_
65-61	11809-11813	25.0	_
65-62	11814-11815	s	_
65-63	11816-11817	)	_
65-64	11818-11819	.	_

Text=The six rigid body movement parameters were also included as regressors in the model in FSL FEAT.
66-1	11820-11823	The	_
66-2	11824-11827	six	_
66-3	11828-11833	rigid	_
66-4	11834-11838	body	_
66-5	11839-11847	movement	_
66-6	11848-11858	parameters	_
66-7	11859-11863	were	_
66-8	11864-11868	also	_
66-9	11869-11877	included	_
66-10	11878-11880	as	_
66-11	11881-11891	regressors	_
66-12	11892-11894	in	_
66-13	11895-11898	the	_
66-14	11899-11904	model	_
66-15	11905-11907	in	_
66-16	11908-11911	FSL	_
66-17	11912-11916	FEAT	_
66-18	11917-11918	.	_

Text=For each participant, first level whole-brain mixed-effects analyses were performed by modelling the MID anticipation periods (i.e.
67-1	11919-11922	For	_
67-2	11923-11927	each	_
67-3	11928-11939	participant	_
67-4	11940-11941	,	_
67-5	11942-11947	first	_
67-6	11948-11953	level	_
67-7	11954-11965	whole-brain	_
67-8	11966-11979	mixed-effects	_
67-9	11980-11988	analyses	_
67-10	11989-11993	were	_
67-11	11994-12003	performed	_
67-12	12004-12006	by	_
67-13	12007-12016	modelling	_
67-14	12017-12020	the	_
67-15	12021-12024	MID	_
67-16	12025-12037	anticipation	_
67-17	12038-12045	periods	_
67-18	12046-12047	(	_
67-19	12048-12051	i.e	_
67-20	12052-12053	.	_

Text=gain, neutral) as explanatory variables within the context of the general linear model on a voxel-by-voxel basis (variable boxcar functions for the cue + variable anticipation period regressors were convolved with the haemodynamic response function).
68-1	12054-12058	gain	_
68-2	12059-12060	,	_
68-3	12061-12068	neutral	_
68-4	12069-12070	)	_
68-5	12071-12073	as	_
68-6	12074-12085	explanatory	_
68-7	12086-12095	variables	_
68-8	12096-12102	within	_
68-9	12103-12106	the	_
68-10	12107-12114	context	_
68-11	12115-12117	of	_
68-12	12118-12121	the	_
68-13	12122-12129	general	_
68-14	12130-12136	linear	_
68-15	12137-12142	model	_
68-16	12143-12145	on	_
68-17	12146-12147	a	_
68-18	12148-12162	voxel-by-voxel	_
68-19	12163-12168	basis	_
68-20	12169-12170	(	_
68-21	12171-12179	variable	_
68-22	12180-12186	boxcar	_
68-23	12187-12196	functions	_
68-24	12197-12200	for	_
68-25	12201-12204	the	_
68-26	12205-12208	cue	_
68-27	12209-12210	+	_
68-28	12211-12219	variable	_
68-29	12220-12232	anticipation	_
68-30	12233-12239	period	_
68-31	12240-12250	regressors	_
68-32	12251-12255	were	_
68-33	12256-12265	convolved	_
68-34	12266-12270	with	_
68-35	12271-12274	the	_
68-36	12275-12287	haemodynamic	_
68-37	12288-12296	response	_
68-38	12297-12305	function	_
68-39	12306-12307	)	_
68-40	12308-12309	.	_

Text=The gain and neutral outcome periods (“ Hit ” and “ Miss ”) were regressed out of the functional time series as conditions of no interest for the analyses reported here.
69-1	12310-12313	The	_
69-2	12314-12318	gain	_
69-3	12319-12322	and	_
69-4	12323-12330	neutral	_
69-5	12331-12338	outcome	_
69-6	12339-12346	periods	_
69-7	12347-12348	(	_
69-8	12349-12350	“	_
69-9	12351-12354	Hit	_
69-10	12355-12356	”	_
69-11	12357-12360	and	_
69-12	12361-12362	“	_
69-13	12363-12367	Miss	_
69-14	12368-12369	”	_
69-15	12370-12371	)	_
69-16	12372-12376	were	_
69-17	12377-12386	regressed	_
69-18	12387-12390	out	_
69-19	12391-12393	of	_
69-20	12394-12397	the	_
69-21	12398-12408	functional	_
69-22	12409-12413	time	_
69-23	12414-12420	series	_
69-24	12421-12423	as	_
69-25	12424-12434	conditions	_
69-26	12435-12437	of	_
69-27	12438-12440	no	_
69-28	12441-12449	interest	_
69-29	12450-12453	for	_
69-30	12454-12457	the	_
69-31	12458-12466	analyses	_
69-32	12467-12475	reported	_
69-33	12476-12480	here	_
69-34	12481-12482	.	_

Text=During these first level analyses, the gain anticipation> neutral anticipation contrast was formulated.
70-1	12483-12489	During	_
70-2	12490-12495	these	_
70-3	12496-12501	first	_
70-4	12502-12507	level	_
70-5	12508-12516	analyses	_
70-6	12517-12518	,	_
70-7	12519-12522	the	_
70-8	12523-12527	gain	_
70-9	12528-12540	anticipation	_
70-10	12541-12542	>	_
70-11	12543-12550	neutral	_
70-12	12551-12563	anticipation	_
70-13	12564-12572	contrast	_
70-14	12573-12576	was	_
70-15	12577-12587	formulated	_
70-16	12588-12589	.	_

Text=Owing to the small number of loss trials in the current task, the lose cue + anticipation and outcome periods (“ Hit ” and “ Miss ”) were additionally regressed out of the functional time series as conditions of no interest.
71-1	12590-12595	Owing	_
71-2	12596-12598	to	_
71-3	12599-12602	the	_
71-4	12603-12608	small	_
71-5	12609-12615	number	_
71-6	12616-12618	of	_
71-7	12619-12623	loss	_
71-8	12624-12630	trials	_
71-9	12631-12633	in	_
71-10	12634-12637	the	_
71-11	12638-12645	current	_
71-12	12646-12650	task	_
71-13	12651-12652	,	_
71-14	12653-12656	the	_
71-15	12657-12661	lose	_
71-16	12662-12665	cue	_
71-17	12666-12667	+	_
71-18	12668-12680	anticipation	_
71-19	12681-12684	and	_
71-20	12685-12692	outcome	_
71-21	12693-12700	periods	_
71-22	12701-12702	(	_
71-23	12703-12704	“	_
71-24	12705-12708	Hit	_
71-25	12709-12710	”	_
71-26	12711-12714	and	_
71-27	12715-12716	“	_
71-28	12717-12721	Miss	_
71-29	12722-12723	”	_
71-30	12724-12725	)	_
71-31	12726-12730	were	_
71-32	12731-12743	additionally	_
71-33	12744-12753	regressed	_
71-34	12754-12757	out	_
71-35	12758-12760	of	_
71-36	12761-12764	the	_
71-37	12765-12775	functional	_
71-38	12776-12780	time	_
71-39	12781-12787	series	_
71-40	12788-12790	as	_
71-41	12791-12801	conditions	_
71-42	12802-12804	of	_
71-43	12805-12807	no	_
71-44	12808-12816	interest	_
71-45	12817-12818	.	_

Text=Therefore, the fewer number of lose trials on the MID task meant we were unable to examine voxel-wise group differences in loss anticipation.
72-1	12819-12828	Therefore	_
72-2	12829-12830	,	_
72-3	12831-12834	the	_
72-4	12835-12840	fewer	_
72-5	12841-12847	number	_
72-6	12848-12850	of	_
72-7	12851-12855	lose	_
72-8	12856-12862	trials	_
72-9	12863-12865	on	_
72-10	12866-12869	the	_
72-11	12870-12873	MID	_
72-12	12874-12878	task	_
72-13	12879-12884	meant	_
72-14	12885-12887	we	_
72-15	12888-12892	were	_
72-16	12893-12899	unable	_
72-17	12900-12902	to	_
72-18	12903-12910	examine	_
72-19	12911-12921	voxel-wise	_
72-20	12922-12927	group	_
72-21	12928-12939	differences	_
72-22	12940-12942	in	_
72-23	12943-12947	loss	_
72-24	12948-12960	anticipation	_
72-25	12961-12962	.	_

Text=The end fixation period of the task served as the implicit baseline.
73-1	12963-12966	The	_
73-2	12967-12970	end	_
73-3	12971-12979	fixation	_
73-4	12980-12986	period	_
73-5	12987-12989	of	_
73-6	12990-12993	the	_
73-7	12994-12998	task	_
73-8	12999-13005	served	_
73-9	13006-13008	as	_
73-10	13009-13012	the	_
73-11	13013-13021	implicit	_
73-12	13022-13030	baseline	_
73-13	13031-13032	.	_

Text=Registration was conducted through a two-step procedure, whereby EPI images were first registered to the high-resolution T1 structural image, then into standard (Montreal Neurological Institute, MNI avg152 template) space, with 12-parameter affine transformations.
74-1	13033-13045	Registration	_
74-2	13046-13049	was	_
74-3	13050-13059	conducted	_
74-4	13060-13067	through	_
74-5	13068-13069	a	_
74-6	13070-13078	two-step	_
74-7	13079-13088	procedure	_
74-8	13089-13090	,	_
74-9	13091-13098	whereby	_
74-10	13099-13102	EPI	_
74-11	13103-13109	images	_
74-12	13110-13114	were	_
74-13	13115-13120	first	_
74-14	13121-13131	registered	_
74-15	13132-13134	to	_
74-16	13135-13138	the	_
74-17	13139-13154	high-resolution	_
74-18	13155-13157	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
74-19	13158-13168	structural	_
74-20	13169-13174	image	_
74-21	13175-13176	,	_
74-22	13177-13181	then	_
74-23	13182-13186	into	_
74-24	13187-13195	standard	_
74-25	13196-13197	(	_
74-26	13198-13206	Montreal	_
74-27	13207-13219	Neurological	_
74-28	13220-13229	Institute	_
74-29	13230-13231	,	_
74-30	13232-13235	MNI	_
74-31	13236-13242	avg152	_
74-32	13243-13251	template	_
74-33	13252-13253	)	_
74-34	13254-13259	space	_
74-35	13260-13261	,	_
74-36	13262-13266	with	_
74-37	13267-13279	12-parameter	_
74-38	13280-13286	affine	_
74-39	13287-13302	transformations	_
74-40	13303-13304	.	_

Text=Higher-level (within group one-sample t-tests and between-group independent samples t-tests) were conducted on the gain anticipation> neutral anticipation contrast using the randomise programme in FSL.
75-1	13305-13317	Higher-level	_
75-2	13318-13319	(	_
75-3	13320-13326	within	_
75-4	13327-13332	group	_
75-5	13333-13343	one-sample	_
75-6	13344-13351	t-tests	_
75-7	13352-13355	and	_
75-8	13356-13369	between-group	_
75-9	13370-13381	independent	_
75-10	13382-13389	samples	_
75-11	13390-13397	t-tests	_
75-12	13398-13399	)	_
75-13	13400-13404	were	_
75-14	13405-13414	conducted	_
75-15	13415-13417	on	_
75-16	13418-13421	the	_
75-17	13422-13426	gain	_
75-18	13427-13439	anticipation	_
75-19	13440-13441	>	_
75-20	13442-13449	neutral	_
75-21	13450-13462	anticipation	_
75-22	13463-13471	contrast	_
75-23	13472-13477	using	_
75-24	13478-13481	the	_
75-25	13482-13491	randomise	_
75-26	13492-13501	programme	_
75-27	13502-13504	in	_
75-28	13505-13508	FSL	_
75-29	13509-13510	.	_

Text=Randomise employs a permutation approach through resampling.
76-1	13511-13520	Randomise	_
76-2	13521-13528	employs	_
76-3	13529-13530	a	_
76-4	13531-13542	permutation	_
76-5	13543-13551	approach	_
76-6	13552-13559	through	_
76-7	13560-13570	resampling	_
76-8	13571-13572	.	_

Text=Significance (PFWE <0.05) for the gain anticipation> neutral anticipation contrast on both the one-sample and independent samples t-tests was conducted taking a threshold-free cluster enhancement (TFCE) approach and using 5000 permutations.
77-1	13573-13585	Significance	_
77-2	13586-13587	(	_
77-3	13588-13592	PFWE	_
77-4	13593-13594	<	_
77-5	13595-13599	0.05	_
77-6	13600-13601	)	_
77-7	13602-13605	for	_
77-8	13606-13609	the	_
77-9	13610-13614	gain	_
77-10	13615-13627	anticipation	_
77-11	13628-13629	>	_
77-12	13630-13637	neutral	_
77-13	13638-13650	anticipation	_
77-14	13651-13659	contrast	_
77-15	13660-13662	on	_
77-16	13663-13667	both	_
77-17	13668-13671	the	_
77-18	13672-13682	one-sample	_
77-19	13683-13686	and	_
77-20	13687-13698	independent	_
77-21	13699-13706	samples	_
77-22	13707-13714	t-tests	_
77-23	13715-13718	was	_
77-24	13719-13728	conducted	_
77-25	13729-13735	taking	_
77-26	13736-13737	a	_
77-27	13738-13752	threshold-free	_
77-28	13753-13760	cluster	_
77-29	13761-13772	enhancement	_
77-30	13773-13774	(	_
77-31	13775-13779	TFCE	_
77-32	13780-13781	)	_
77-33	13782-13790	approach	_
77-34	13791-13794	and	_
77-35	13795-13800	using	_
77-36	13801-13805	5000	_
77-37	13806-13818	permutations	_
77-38	13819-13820	.	_

Text=TFCE aims to maintain the sensitivity of cluster-based thresholding, while avoiding the arbitrary nature of threshold choice.
78-1	13821-13825	TFCE	_
78-2	13826-13830	aims	_
78-3	13831-13833	to	_
78-4	13834-13842	maintain	_
78-5	13843-13846	the	_
78-6	13847-13858	sensitivity	_
78-7	13859-13861	of	_
78-8	13862-13875	cluster-based	_
78-9	13876-13888	thresholding	_
78-10	13889-13890	,	_
78-11	13891-13896	while	_
78-12	13897-13905	avoiding	_
78-13	13906-13909	the	_
78-14	13910-13919	arbitrary	_
78-15	13920-13926	nature	_
78-16	13927-13929	of	_
78-17	13930-13939	threshold	_
78-18	13940-13946	choice	_
78-19	13947-13948	.	_

Text=Given the differences in scanners across the three sites, these analyses were conducted while also controlling for study site.
79-1	13949-13954	Given	_
79-2	13955-13958	the	_
79-3	13959-13970	differences	_
79-4	13971-13973	in	_
79-5	13974-13982	scanners	_
79-6	13983-13989	across	_
79-7	13990-13993	the	_
79-8	13994-13999	three	_
79-9	14000-14005	sites	_
79-10	14006-14007	,	_
79-11	14008-14013	these	_
79-12	14014-14022	analyses	_
79-13	14023-14027	were	_
79-14	14028-14037	conducted	_
79-15	14038-14043	while	_
79-16	14044-14048	also	_
79-17	14049-14060	controlling	_
79-18	14061-14064	for	_
79-19	14065-14070	study	_
79-20	14071-14075	site	_
79-21	14076-14077	.	_

Text=Trial-Wise beta value image analyses Data pre-processing was also initially conducted using FEAT (fMRI Expert Analysis Tool) from the FMRIB Software Library (www.fmrib.ox.ac.uk/fsl) as described above.
80-1	14078-14088	Trial-Wise	_
80-2	14089-14093	beta	_
80-3	14094-14099	value	_
80-4	14100-14105	image	_
80-5	14106-14114	analyses	_
80-6	14115-14119	Data	_
80-7	14120-14134	pre-processing	_
80-8	14135-14138	was	_
80-9	14139-14143	also	_
80-10	14144-14153	initially	_
80-11	14154-14163	conducted	_
80-12	14164-14169	using	_
80-13	14170-14174	FEAT	_
80-14	14175-14176	(	_
80-15	14177-14181	fMRI	_
80-16	14182-14188	Expert	_
80-17	14189-14197	Analysis	_
80-18	14198-14202	Tool	_
80-19	14203-14204	)	_
80-20	14205-14209	from	_
80-21	14210-14213	the	_
80-22	14214-14219	FMRIB	_
80-23	14220-14228	Software	_
80-24	14229-14236	Library	_
80-25	14237-14238	(	_
80-26	14239-14261	www.fmrib.ox.ac.uk/fsl	_
80-27	14262-14263	)	_
80-28	14264-14266	as	_
80-29	14267-14276	described	_
80-30	14277-14282	above	_
80-31	14283-14284	.	_

Text=For each participant, each individual gain and neutral anticipation epoch (cue + variable anticipation period) was separately modelled within the context of the general linear model.
81-1	14285-14288	For	_
81-2	14289-14293	each	_
81-3	14294-14305	participant	_
81-4	14306-14307	,	_
81-5	14308-14312	each	_
81-6	14313-14323	individual	_
81-7	14324-14328	gain	_
81-8	14329-14332	and	_
81-9	14333-14340	neutral	_
81-10	14341-14353	anticipation	_
81-11	14354-14359	epoch	_
81-12	14360-14361	(	_
81-13	14362-14365	cue	_
81-14	14366-14367	+	_
81-15	14368-14376	variable	_
81-16	14377-14389	anticipation	_
81-17	14390-14396	period	_
81-18	14397-14398	)	_
81-19	14399-14402	was	_
81-20	14403-14413	separately	_
81-21	14414-14422	modelled	_
81-22	14423-14429	within	_
81-23	14430-14433	the	_
81-24	14434-14441	context	_
81-25	14442-14444	of	_
81-26	14445-14448	the	_
81-27	14449-14456	general	_
81-28	14457-14463	linear	_
81-29	14464-14469	model	_
81-30	14470-14471	.	_

Text=This approach yielded a total of 18 unique beta value images for each of the gain and neutral anticipation conditions on each run of the MID task.
82-1	14472-14476	This	_
82-2	14477-14485	approach	_
82-3	14486-14493	yielded	_
82-4	14494-14495	a	_
82-5	14496-14501	total	_
82-6	14502-14504	of	_
82-7	14505-14507	18	_
82-8	14508-14514	unique	_
82-9	14515-14519	beta	_
82-10	14520-14525	value	_
82-11	14526-14532	images	_
82-12	14533-14536	for	_
82-13	14537-14541	each	_
82-14	14542-14544	of	_
82-15	14545-14548	the	_
82-16	14549-14553	gain	_
82-17	14554-14557	and	_
82-18	14558-14565	neutral	_
82-19	14566-14578	anticipation	_
82-20	14579-14589	conditions	_
82-21	14590-14592	on	_
82-22	14593-14597	each	_
82-23	14598-14601	run	_
82-24	14602-14604	of	_
82-25	14605-14608	the	_
82-26	14609-14612	MID	http://maven.renci.org/NeuroBridge/neurobridge#ExtrapyramidalDisease
82-27	14613-14617	task	_
82-28	14618-14619	.	_

Text=This meant that each voxel-wise beta value image reflected the magnitude of the hemodynamic response evoked by each of the gain and neutral anticipation epochs.
83-1	14620-14624	This	_
83-2	14625-14630	meant	_
83-3	14631-14635	that	_
83-4	14636-14640	each	_
83-5	14641-14651	voxel-wise	_
83-6	14652-14656	beta	_
83-7	14657-14662	value	_
83-8	14663-14668	image	_
83-9	14669-14678	reflected	_
83-10	14679-14682	the	_
83-11	14683-14692	magnitude	_
83-12	14693-14695	of	_
83-13	14696-14699	the	_
83-14	14700-14711	hemodynamic	_
83-15	14712-14720	response	_
83-16	14721-14727	evoked	_
83-17	14728-14730	by	_
83-18	14731-14735	each	_
83-19	14736-14738	of	_
83-20	14739-14742	the	_
83-21	14743-14747	gain	_
83-22	14748-14751	and	_
83-23	14752-14759	neutral	_
83-24	14760-14772	anticipation	_
83-25	14773-14779	epochs	_
83-26	14780-14781	.	_

Text=Each beta value image for each MID run was then subsequently registered into standard (MNI avg152 template) space before being concatenated to generate a beta value “ trial-wise ” (e.g., gain anticipation) time series.
84-1	14782-14786	Each	_
84-2	14787-14791	beta	_
84-3	14792-14797	value	_
84-4	14798-14803	image	_
84-5	14804-14807	for	_
84-6	14808-14812	each	_
84-7	14813-14816	MID	_
84-8	14817-14820	run	_
84-9	14821-14824	was	_
84-10	14825-14829	then	_
84-11	14830-14842	subsequently	_
84-12	14843-14853	registered	_
84-13	14854-14858	into	_
84-14	14859-14867	standard	_
84-15	14868-14869	(	_
84-16	14870-14873	MNI	_
84-17	14874-14880	avg152	_
84-18	14881-14889	template	_
84-19	14890-14891	)	_
84-20	14892-14897	space	_
84-21	14898-14904	before	_
84-22	14905-14910	being	_
84-23	14911-14923	concatenated	_
84-24	14924-14926	to	_
84-25	14927-14935	generate	_
84-26	14936-14937	a	_
84-27	14938-14942	beta	_
84-28	14943-14948	value	_
84-29	14949-14950	“	_
84-30	14951-14961	trial-wise	_
84-31	14962-14963	”	_
84-32	14964-14965	(	_
84-33	14966-14970	e.g.	_
84-34	14971-14972	,	_
84-35	14973-14977	gain	_
84-36	14978-14990	anticipation	_
84-37	14991-14992	)	_
84-38	14993-14997	time	_
84-39	14998-15004	series	_
84-40	15005-15006	.	_

Text=Each beta value trial-wise time series for each MID run was further concatenated across runs to generate a single beta value trial-wise time series for the gain and neutral MID anticipation conditions.
85-1	15007-15011	Each	_
85-2	15012-15016	beta	_
85-3	15017-15022	value	_
85-4	15023-15033	trial-wise	_
85-5	15034-15038	time	_
85-6	15039-15045	series	_
85-7	15046-15049	for	_
85-8	15050-15054	each	_
85-9	15055-15058	MID	_
85-10	15059-15062	run	_
85-11	15063-15066	was	_
85-12	15067-15074	further	_
85-13	15075-15087	concatenated	_
85-14	15088-15094	across	_
85-15	15095-15099	runs	_
85-16	15100-15102	to	_
85-17	15103-15111	generate	_
85-18	15112-15113	a	_
85-19	15114-15120	single	_
85-20	15121-15125	beta	_
85-21	15126-15131	value	_
85-22	15132-15142	trial-wise	_
85-23	15143-15147	time	_
85-24	15148-15154	series	_
85-25	15155-15158	for	_
85-26	15159-15162	the	_
85-27	15163-15167	gain	_
85-28	15168-15171	and	_
85-29	15172-15179	neutral	_
85-30	15180-15183	MID	_
85-31	15184-15196	anticipation	_
85-32	15197-15207	conditions	_
85-33	15208-15209	.	_

Text=This procedure yielded a thirty-six beta value trial-wise time series image for each participant for the gain and neutral anticipation conditions.
86-1	15210-15214	This	_
86-2	15215-15224	procedure	_
86-3	15225-15232	yielded	_
86-4	15233-15234	a	_
86-5	15235-15245	thirty-six	_
86-6	15246-15250	beta	_
86-7	15251-15256	value	_
86-8	15257-15267	trial-wise	_
86-9	15268-15272	time	_
86-10	15273-15279	series	_
86-11	15280-15285	image	_
86-12	15286-15289	for	_
86-13	15290-15294	each	_
86-14	15295-15306	participant	_
86-15	15307-15310	for	_
86-16	15311-15314	the	_
86-17	15315-15319	gain	_
86-18	15320-15323	and	_
86-19	15324-15331	neutral	_
86-20	15332-15344	anticipation	_
86-21	15345-15355	conditions	_
86-22	15356-15357	.	_

Text=The neutral trial-wise time series was then simply subtracted from the gain trial-wise time series to yield a gain anticipation> neutral anticipation contrast time series (see Supplementary Fig.
87-1	15358-15361	The	_
87-2	15362-15369	neutral	_
87-3	15370-15380	trial-wise	_
87-4	15381-15385	time	_
87-5	15386-15392	series	_
87-6	15393-15396	was	_
87-7	15397-15401	then	_
87-8	15402-15408	simply	_
87-9	15409-15419	subtracted	_
87-10	15420-15424	from	_
87-11	15425-15428	the	_
87-12	15429-15433	gain	_
87-13	15434-15444	trial-wise	_
87-14	15445-15449	time	_
87-15	15450-15456	series	_
87-16	15457-15459	to	_
87-17	15460-15465	yield	_
87-18	15466-15467	a	_
87-19	15468-15472	gain	_
87-20	15473-15485	anticipation	_
87-21	15486-15487	>	_
87-22	15488-15495	neutral	_
87-23	15496-15508	anticipation	_
87-24	15509-15517	contrast	_
87-25	15518-15522	time	_
87-26	15523-15529	series	_
87-27	15530-15531	(	_
87-28	15532-15535	see	_
87-29	15536-15549	Supplementary	_
87-30	15550-15553	Fig	_
87-31	15554-15555	.	_

Text=1).
88-1	15556-15557	1	_
88-2	15558-15559	)	_
88-3	15560-15561	.	_

Text=This beta value trial-wise time series method has been previously used to examine connectivity during cognitive tasks, including the MID task.
89-1	15562-15566	This	_
89-2	15567-15571	beta	_
89-3	15572-15577	value	_
89-4	15578-15588	trial-wise	_
89-5	15589-15593	time	_
89-6	15594-15600	series	_
89-7	15601-15607	method	_
89-8	15608-15611	has	_
89-9	15612-15616	been	_
89-10	15617-15627	previously	_
89-11	15628-15632	used	_
89-12	15633-15635	to	_
89-13	15636-15643	examine	_
89-14	15644-15656	connectivity	_
89-15	15657-15663	during	_
89-16	15664-15673	cognitive	_
89-17	15674-15679	tasks	_
89-18	15680-15681	,	_
89-19	15682-15691	including	_
89-20	15692-15695	the	_
89-21	15696-15699	MID	http://maven.renci.org/NeuroBridge/neurobridge#ExtrapyramidalDisease
89-22	15700-15704	task	_
89-23	15705-15706	.	_

Text=The small, variable (performance-dependent) number of events for the outcome periods (“ hits ” and “ misses ”), and the small number of loss trials in the task, meant that we could not generate trial-wise beta value images for these events.
90-1	15707-15710	The	_
90-2	15711-15716	small	_
90-3	15717-15718	,	_
90-4	15719-15727	variable	_
90-5	15728-15729	(	_
90-6	15730-15751	performance-dependent	_
90-7	15752-15753	)	_
90-8	15754-15760	number	_
90-9	15761-15763	of	_
90-10	15764-15770	events	_
90-11	15771-15774	for	_
90-12	15775-15778	the	_
90-13	15779-15786	outcome	_
90-14	15787-15794	periods	_
90-15	15795-15796	(	_
90-16	15797-15798	“	_
90-17	15799-15803	hits	_
90-18	15804-15805	”	_
90-19	15806-15809	and	_
90-20	15810-15811	“	_
90-21	15812-15818	misses	_
90-22	15819-15820	”	_
90-23	15821-15822	)	_
90-24	15823-15824	,	_
90-25	15825-15828	and	_
90-26	15829-15832	the	_
90-27	15833-15838	small	_
90-28	15839-15845	number	_
90-29	15846-15848	of	_
90-30	15849-15853	loss	_
90-31	15854-15860	trials	_
90-32	15861-15863	in	_
90-33	15864-15867	the	_
90-34	15868-15872	task	_
90-35	15873-15874	,	_
90-36	15875-15880	meant	_
90-37	15881-15885	that	_
90-38	15886-15888	we	_
90-39	15889-15894	could	_
90-40	15895-15898	not	_
90-41	15899-15907	generate	_
90-42	15908-15918	trial-wise	_
90-43	15919-15923	beta	_
90-44	15924-15929	value	_
90-45	15930-15936	images	_
90-46	15937-15940	for	_
90-47	15941-15946	these	_
90-48	15947-15953	events	_
90-49	15954-15955	.	_

Text=Therefore, gain and neutral outcome (well as lose anticipation and outcome) events were regressed out of the functional time series as conditions of no interest during the first level analyses.
91-1	15956-15965	Therefore	_
91-2	15966-15967	,	_
91-3	15968-15972	gain	_
91-4	15973-15976	and	_
91-5	15977-15984	neutral	_
91-6	15985-15992	outcome	_
91-7	15993-15994	(	_
91-8	15995-15999	well	_
91-9	16000-16002	as	_
91-10	16003-16007	lose	_
91-11	16008-16020	anticipation	_
91-12	16021-16024	and	_
91-13	16025-16032	outcome	_
91-14	16033-16034	)	_
91-15	16035-16041	events	_
91-16	16042-16046	were	_
91-17	16047-16056	regressed	_
91-18	16057-16060	out	_
91-19	16061-16063	of	_
91-20	16064-16067	the	_
91-21	16068-16078	functional	_
91-22	16079-16083	time	_
91-23	16084-16090	series	_
91-24	16091-16093	as	_
91-25	16094-16104	conditions	_
91-26	16105-16107	of	_
91-27	16108-16110	no	_
91-28	16111-16119	interest	_
91-29	16120-16126	during	_
91-30	16127-16130	the	_
91-31	16131-16136	first	_
91-32	16137-16142	level	_
91-33	16143-16151	analyses	_
91-34	16152-16153	.	_

Text=This meant that the same end fixation period of the task also served as the implicit baseline for these analyses.
92-1	16154-16158	This	_
92-2	16159-16164	meant	_
92-3	16165-16169	that	_
92-4	16170-16173	the	_
92-5	16174-16178	same	_
92-6	16179-16182	end	_
92-7	16183-16191	fixation	_
92-8	16192-16198	period	_
92-9	16199-16201	of	_
92-10	16202-16205	the	_
92-11	16206-16210	task	_
92-12	16211-16215	also	_
92-13	16216-16222	served	_
92-14	16223-16225	as	_
92-15	16226-16229	the	_
92-16	16230-16238	implicit	_
92-17	16239-16247	baseline	_
92-18	16248-16251	for	_
92-19	16252-16257	these	_
92-20	16258-16266	analyses	_
92-21	16267-16268	.	_

Text=Time series Extraction and correlation matrices Using the Harvard-Oxford atlas (96 cortical and 14 subcortical nodes/regions) as our connectome of interest, we used the fslmeants programme to extract the mean beta value time series from each of 110 anatomical regions of interest (ROI) for the gain anticipation> neutral contrast beta image for each participant.
93-1	16269-16273	Time	_
93-2	16274-16280	series	_
93-3	16281-16291	Extraction	_
93-4	16292-16295	and	_
93-5	16296-16307	correlation	_
93-6	16308-16316	matrices	_
93-7	16317-16322	Using	_
93-8	16323-16326	the	_
93-9	16327-16341	Harvard-Oxford	_
93-10	16342-16347	atlas	_
93-11	16348-16349	(	_
93-12	16350-16352	96	_
93-13	16353-16361	cortical	_
93-14	16362-16365	and	_
93-15	16366-16368	14	_
93-16	16369-16380	subcortical	_
93-17	16381-16394	nodes/regions	_
93-18	16395-16396	)	_
93-19	16397-16399	as	_
93-20	16400-16403	our	_
93-21	16404-16414	connectome	_
93-22	16415-16417	of	_
93-23	16418-16426	interest	_
93-24	16427-16428	,	_
93-25	16429-16431	we	_
93-26	16432-16436	used	_
93-27	16437-16440	the	_
93-28	16441-16450	fslmeants	_
93-29	16451-16460	programme	_
93-30	16461-16463	to	_
93-31	16464-16471	extract	_
93-32	16472-16475	the	_
93-33	16476-16480	mean	_
93-34	16481-16485	beta	_
93-35	16486-16491	value	_
93-36	16492-16496	time	_
93-37	16497-16503	series	_
93-38	16504-16508	from	_
93-39	16509-16513	each	_
93-40	16514-16516	of	_
93-41	16517-16520	110	_
93-42	16521-16531	anatomical	_
93-43	16532-16539	regions	_
93-44	16540-16542	of	_
93-45	16543-16551	interest	_
93-46	16552-16553	(	_
93-47	16554-16557	ROI	_
93-48	16558-16559	)	_
93-49	16560-16563	for	_
93-50	16564-16567	the	_
93-51	16568-16572	gain	_
93-52	16573-16585	anticipation	_
93-53	16586-16587	>	_
93-54	16588-16595	neutral	_
93-55	16596-16604	contrast	_
93-56	16605-16609	beta	_
93-57	16610-16615	image	_
93-58	16616-16619	for	_
93-59	16620-16624	each	_
93-60	16625-16636	participant	_
93-61	16637-16638	.	_

Text=Using these mean ROI time series outputs, we then conducted Pearson correlation coefficient analyses to construct whole brain ROI‐to‐ROI pairwise matrices (see Supplementary Fig.
94-1	16639-16644	Using	_
94-2	16645-16650	these	_
94-3	16651-16655	mean	_
94-4	16656-16659	ROI	_
94-5	16660-16664	time	_
94-6	16665-16671	series	_
94-7	16672-16679	outputs	_
94-8	16680-16681	,	_
94-9	16682-16684	we	_
94-10	16685-16689	then	_
94-11	16690-16699	conducted	_
94-12	16700-16707	Pearson	_
94-13	16708-16719	correlation	_
94-14	16720-16731	coefficient	_
94-15	16732-16740	analyses	_
94-16	16741-16743	to	_
94-17	16744-16753	construct	_
94-18	16754-16759	whole	_
94-19	16760-16765	brain	_
94-20	16766-16776	ROI‐to‐ROI	_
94-21	16777-16785	pairwise	_
94-22	16786-16794	matrices	_
94-23	16795-16796	(	_
94-24	16797-16800	see	_
94-25	16801-16814	Supplementary	_
94-26	16815-16818	Fig	_
94-27	16819-16820	.	_

Text=1).
95-1	16821-16822	1	_
95-2	16823-16824	)	_
95-3	16825-16826	.	_

Text=Each matrix was made up of 5995 (=N * (N − 1) /2, with N = 110 nodes) pairwise connections (edges).
96-1	16827-16831	Each	_
96-2	16832-16838	matrix	_
96-3	16839-16842	was	_
96-4	16843-16847	made	_
96-5	16848-16850	up	_
96-6	16851-16853	of	_
96-7	16854-16858	5995	_
96-8	16859-16860	(	_
96-9	16861-16863	=N	_
96-10	16864-16865	*	_
96-11	16866-16867	(	_
96-12	16868-16869	N	_
96-13	16870-16871	−	_
96-14	16872-16873	1	_
96-15	16874-16875	)	_
96-16	16876-16878	/2	_
96-17	16879-16880	,	_
96-18	16881-16885	with	_
96-19	16886-16887	N	_
96-20	16888-16889	=	_
96-21	16890-16893	110	_
96-22	16894-16899	nodes	_
96-23	16900-16901	)	_
96-24	16902-16910	pairwise	_
96-25	16911-16922	connections	_
96-26	16923-16924	(	_
96-27	16925-16930	edges	_
96-28	16931-16932	)	_
96-29	16933-16934	.	_

Text=These matrices were generated in MATLAB (The MathWorks, Inc., Natick, Massachusetts, United States) and used to compare network connectivity between the CON and ADD groups (see below).
97-1	16935-16940	These	_
97-2	16941-16949	matrices	_
97-3	16950-16954	were	_
97-4	16955-16964	generated	_
97-5	16965-16967	in	_
97-6	16968-16974	MATLAB	_
97-7	16975-16976	(	_
97-8	16977-16980	The	_
97-9	16981-16990	MathWorks	_
97-10	16991-16992	,	_
97-11	16993-16997	Inc.	_
97-12	16998-16999	,	_
97-13	17000-17006	Natick	_
97-14	17007-17008	,	_
97-15	17009-17022	Massachusetts	_
97-16	17023-17024	,	_
97-17	17025-17031	United	_
97-18	17032-17038	States	_
97-19	17039-17040	)	_
97-20	17041-17044	and	_
97-21	17045-17049	used	_
97-22	17050-17052	to	_
97-23	17053-17060	compare	_
97-24	17061-17068	network	_
97-25	17069-17081	connectivity	_
97-26	17082-17089	between	_
97-27	17090-17093	the	_
97-28	17094-17097	CON	_
97-29	17098-17101	and	_
97-30	17102-17105	ADD	_
97-31	17106-17112	groups	_
97-32	17113-17114	(	_
97-33	17115-17118	see	_
97-34	17119-17124	below	_
97-35	17125-17126	)	_
97-36	17127-17128	.	_

Text=Graph measures Global (characteristic path length and clustering coefficient) graph measures were estimated from each correlation matrix using the GraphVar (www.rfmri.org/GraphVar) toolbox for functional brain connectivity in MATLAB (The MathWorks, Inc., Natick, Massachusetts, United States).
98-1	17129-17134	Graph	_
98-2	17135-17143	measures	_
98-3	17144-17150	Global	_
98-4	17151-17152	(	_
98-5	17153-17167	characteristic	_
98-6	17168-17172	path	_
98-7	17173-17179	length	_
98-8	17180-17183	and	_
98-9	17184-17194	clustering	_
98-10	17195-17206	coefficient	_
98-11	17207-17208	)	_
98-12	17209-17214	graph	_
98-13	17215-17223	measures	_
98-14	17224-17228	were	_
98-15	17229-17238	estimated	_
98-16	17239-17243	from	_
98-17	17244-17248	each	_
98-18	17249-17260	correlation	_
98-19	17261-17267	matrix	_
98-20	17268-17273	using	_
98-21	17274-17277	the	_
98-22	17278-17286	GraphVar	_
98-23	17287-17288	(	_
98-24	17289-17311	www.rfmri.org/GraphVar	_
98-25	17312-17313	)	_
98-26	17314-17321	toolbox	_
98-27	17322-17325	for	_
98-28	17326-17336	functional	_
98-29	17337-17342	brain	_
98-30	17343-17355	connectivity	_
98-31	17356-17358	in	_
98-32	17359-17365	MATLAB	_
98-33	17366-17367	(	_
98-34	17368-17371	The	_
98-35	17372-17381	MathWorks	_
98-36	17382-17383	,	_
98-37	17384-17388	Inc.	_
98-38	17389-17390	,	_
98-39	17391-17397	Natick	_
98-40	17398-17399	,	_
98-41	17400-17413	Massachusetts	_
98-42	17414-17415	,	_
98-43	17416-17422	United	_
98-44	17423-17429	States	_
98-45	17430-17431	)	_
98-46	17432-17433	.	_

Text=More detailed descriptions of brain network graph measures can be found elsewhere, but we will briefly describe these metrics here.
99-1	17434-17438	More	_
99-2	17439-17447	detailed	_
99-3	17448-17460	descriptions	_
99-4	17461-17463	of	_
99-5	17464-17469	brain	_
99-6	17470-17477	network	_
99-7	17478-17483	graph	_
99-8	17484-17492	measures	_
99-9	17493-17496	can	_
99-10	17497-17499	be	_
99-11	17500-17505	found	_
99-12	17506-17515	elsewhere	_
99-13	17516-17517	,	_
99-14	17518-17521	but	_
99-15	17522-17524	we	_
99-16	17525-17529	will	_
99-17	17530-17537	briefly	_
99-18	17538-17546	describe	_
99-19	17547-17552	these	_
99-20	17553-17560	metrics	_
99-21	17561-17565	here	_
99-22	17566-17567	.	_

Text=Characteristic path length is the minimum number of edges that must be traversed to go from one node (brain region) to another in a network.
100-1	17568-17582	Characteristic	_
100-2	17583-17587	path	_
100-3	17588-17594	length	_
100-4	17595-17597	is	_
100-5	17598-17601	the	_
100-6	17602-17609	minimum	_
100-7	17610-17616	number	_
100-8	17617-17619	of	_
100-9	17620-17625	edges	_
100-10	17626-17630	that	_
100-11	17631-17635	must	_
100-12	17636-17638	be	_
100-13	17639-17648	traversed	_
100-14	17649-17651	to	_
100-15	17652-17654	go	_
100-16	17655-17659	from	_
100-17	17660-17663	one	_
100-18	17664-17668	node	_
100-19	17669-17670	(	_
100-20	17671-17676	brain	_
100-21	17677-17683	region	_
100-22	17684-17685	)	_
100-23	17686-17688	to	_
100-24	17689-17696	another	_
100-25	17697-17699	in	_
100-26	17700-17701	a	_
100-27	17702-17709	network	_
100-28	17710-17711	.	_

Text=For a pair of nodes that are nearest neighbours, the path length is 1.
101-1	17712-17715	For	_
101-2	17716-17717	a	_
101-3	17718-17722	pair	_
101-4	17723-17725	of	_
101-5	17726-17731	nodes	_
101-6	17732-17736	that	_
101-7	17737-17740	are	_
101-8	17741-17748	nearest	_
101-9	17749-17759	neighbours	_
101-10	17760-17761	,	_
101-11	17762-17765	the	_
101-12	17766-17770	path	_
101-13	17771-17777	length	_
101-14	17778-17780	is	_
101-15	17781-17782	1	_
101-16	17783-17784	.	_

Text=The clustering coefficient, by contrast, quantifies the density of connections between the nearest neighbour of a node, and describes how segregated the network is.
102-1	17785-17788	The	_
102-2	17789-17799	clustering	_
102-3	17800-17811	coefficient	_
102-4	17812-17813	,	_
102-5	17814-17816	by	_
102-6	17817-17825	contrast	_
102-7	17826-17827	,	_
102-8	17828-17838	quantifies	_
102-9	17839-17842	the	_
102-10	17843-17850	density	_
102-11	17851-17853	of	_
102-12	17854-17865	connections	_
102-13	17866-17873	between	_
102-14	17874-17877	the	_
102-15	17878-17885	nearest	_
102-16	17886-17895	neighbour	_
102-17	17896-17898	of	_
102-18	17899-17900	a	_
102-19	17901-17905	node	_
102-20	17906-17907	,	_
102-21	17908-17911	and	_
102-22	17912-17921	describes	_
102-23	17922-17925	how	_
102-24	17926-17936	segregated	_
102-25	17937-17940	the	_
102-26	17941-17948	network	_
102-27	17949-17951	is	_
102-28	17952-17953	.	_

Text=The path and clustering measures are first estimated at each node of the connectome before an average (global value) is computed for the entire connectome for each participant ’ s correlation matrix.
103-1	17954-17957	The	_
103-2	17958-17962	path	_
103-3	17963-17966	and	_
103-4	17967-17977	clustering	_
103-5	17978-17986	measures	_
103-6	17987-17990	are	_
103-7	17991-17996	first	_
103-8	17997-18006	estimated	_
103-9	18007-18009	at	_
103-10	18010-18014	each	_
103-11	18015-18019	node	_
103-12	18020-18022	of	_
103-13	18023-18026	the	_
103-14	18027-18037	connectome	_
103-15	18038-18044	before	_
103-16	18045-18047	an	_
103-17	18048-18055	average	_
103-18	18056-18057	(	_
103-19	18058-18064	global	_
103-20	18065-18070	value	_
103-21	18071-18072	)	_
103-22	18073-18075	is	_
103-23	18076-18084	computed	_
103-24	18085-18088	for	_
103-25	18089-18092	the	_
103-26	18093-18099	entire	_
103-27	18100-18110	connectome	_
103-28	18111-18114	for	_
103-29	18115-18119	each	_
103-30	18120-18131	participant	_
103-31	18132-18133	’	_
103-32	18134-18135	s	_
103-33	18136-18147	correlation	_
103-34	18148-18154	matrix	_
103-35	18155-18156	.	_

Text=Graph measures for each participant were then estimated by thresholding each matrix at a selection of proportional cost (K) thresholds – i.e.
104-1	18157-18162	Graph	_
104-2	18163-18171	measures	_
104-3	18172-18175	for	_
104-4	18176-18180	each	_
104-5	18181-18192	participant	_
104-6	18193-18197	were	_
104-7	18198-18202	then	_
104-8	18203-18212	estimated	_
104-9	18213-18215	by	_
104-10	18216-18228	thresholding	_
104-11	18229-18233	each	_
104-12	18234-18240	matrix	_
104-13	18241-18243	at	_
104-14	18244-18245	a	_
104-15	18246-18255	selection	_
104-16	18256-18258	of	_
104-17	18259-18271	proportional	_
104-18	18272-18276	cost	_
104-19	18277-18278	(	_
104-20	18279-18280	K	_
104-21	18281-18282	)	_
104-22	18283-18293	thresholds	_
104-23	18294-18295	–	_
104-24	18296-18299	i.e	_
104-25	18300-18301	.	_

Text=thresholds that retain only a percentage of the strongest connections (edges) in the network.
105-1	18302-18312	thresholds	_
105-2	18313-18317	that	_
105-3	18318-18324	retain	_
105-4	18325-18329	only	_
105-5	18330-18331	a	_
105-6	18332-18342	percentage	_
105-7	18343-18345	of	_
105-8	18346-18349	the	_
105-9	18350-18359	strongest	_
105-10	18360-18371	connections	_
105-11	18372-18373	(	_
105-12	18374-18379	edges	_
105-13	18380-18381	)	_
105-14	18382-18384	in	_
105-15	18385-18388	the	_
105-16	18389-18396	network	_
105-17	18397-18398	.	_

Text=Biological networks are represented by sparse connections, however, and thresholding is a necessary step to extract the appropriate topological properties of networks.
106-1	18399-18409	Biological	_
106-2	18410-18418	networks	_
106-3	18419-18422	are	_
106-4	18423-18434	represented	_
106-5	18435-18437	by	_
106-6	18438-18444	sparse	_
106-7	18445-18456	connections	_
106-8	18457-18458	,	_
106-9	18459-18466	however	_
106-10	18467-18468	,	_
106-11	18469-18472	and	_
106-12	18473-18485	thresholding	_
106-13	18486-18488	is	_
106-14	18489-18490	a	_
106-15	18491-18500	necessary	_
106-16	18501-18505	step	_
106-17	18506-18508	to	_
106-18	18509-18516	extract	_
106-19	18517-18520	the	_
106-20	18521-18532	appropriate	_
106-21	18533-18544	topological	_
106-22	18545-18555	properties	_
106-23	18556-18558	of	_
106-24	18559-18567	networks	_
106-25	18568-18569	.	_

Text=Because graph measures can also be sensitive to threshold value, we have reported our measures across a range of K thresholds (1 ⩽ K ⩽ 5, increments of 1).
107-1	18570-18577	Because	_
107-2	18578-18583	graph	_
107-3	18584-18592	measures	_
107-4	18593-18596	can	_
107-5	18597-18601	also	_
107-6	18602-18604	be	_
107-7	18605-18614	sensitive	_
107-8	18615-18617	to	_
107-9	18618-18627	threshold	_
107-10	18628-18633	value	_
107-11	18634-18635	,	_
107-12	18636-18638	we	_
107-13	18639-18643	have	_
107-14	18644-18652	reported	_
107-15	18653-18656	our	_
107-16	18657-18665	measures	_
107-17	18666-18672	across	_
107-18	18673-18674	a	_
107-19	18675-18680	range	_
107-20	18681-18683	of	_
107-21	18684-18685	K	_
107-22	18686-18696	thresholds	_
107-23	18697-18698	(	_
107-24	18699-18700	1	_
107-25	18701-18702	⩽	_
107-26	18703-18704	K	_
107-27	18705-18706	⩽	_
107-28	18707-18708	5	_
107-29	18709-18710	,	_
107-30	18711-18721	increments	_
107-31	18722-18724	of	_
107-32	18725-18726	1	_
107-33	18727-18728	)	_
107-34	18729-18730	.	_

Text=Here K represents the percentage (e.g., 1 = 10%) number of edges in each matrix that are maintained following thresholding.
108-1	18731-18735	Here	_
108-2	18736-18737	K	_
108-3	18738-18748	represents	_
108-4	18749-18752	the	_
108-5	18753-18763	percentage	_
108-6	18764-18765	(	_
108-7	18766-18770	e.g.	_
108-8	18771-18772	,	_
108-9	18773-18774	1	_
108-10	18775-18776	=	_
108-11	18777-18779	10	_
108-12	18780-18781	%	_
108-13	18782-18783	)	_
108-14	18784-18790	number	_
108-15	18791-18793	of	_
108-16	18794-18799	edges	_
108-17	18800-18802	in	_
108-18	18803-18807	each	_
108-19	18808-18814	matrix	_
108-20	18815-18819	that	_
108-21	18820-18823	are	_
108-22	18824-18834	maintained	_
108-23	18835-18844	following	_
108-24	18845-18857	thresholding	_
108-25	18858-18859	.	_

Text=We employed a range of thresholds to represent the lower and upper bound of a small-world system, and that preserve only the strongest functional connections for efficient parallel information processing at a relatively low wiring cost.
109-1	18860-18862	We	_
109-2	18863-18871	employed	_
109-3	18872-18873	a	_
109-4	18874-18879	range	_
109-5	18880-18882	of	_
109-6	18883-18893	thresholds	_
109-7	18894-18896	to	_
109-8	18897-18906	represent	_
109-9	18907-18910	the	_
109-10	18911-18916	lower	_
109-11	18917-18920	and	_
109-12	18921-18926	upper	_
109-13	18927-18932	bound	_
109-14	18933-18935	of	_
109-15	18936-18937	a	_
109-16	18938-18949	small-world	_
109-17	18950-18956	system	_
109-18	18957-18958	,	_
109-19	18959-18962	and	_
109-20	18963-18967	that	_
109-21	18968-18976	preserve	_
109-22	18977-18981	only	_
109-23	18982-18985	the	_
109-24	18986-18995	strongest	_
109-25	18996-19006	functional	_
109-26	19007-19018	connections	_
109-27	19019-19022	for	_
109-28	19023-19032	efficient	_
109-29	19033-19041	parallel	_
109-30	19042-19053	information	_
109-31	19054-19064	processing	_
109-32	19065-19067	at	_
109-33	19068-19069	a	_
109-34	19070-19080	relatively	_
109-35	19081-19084	low	_
109-36	19085-19091	wiring	_
109-37	19092-19096	cost	_
109-38	19097-19098	.	_

Text=All graph measures were computed from matrices in their weighted form following this thresholding procedure.
110-1	19099-19102	All	_
110-2	19103-19108	graph	_
110-3	19109-19117	measures	_
110-4	19118-19122	were	_
110-5	19123-19131	computed	_
110-6	19132-19136	from	_
110-7	19137-19145	matrices	_
110-8	19146-19148	in	_
110-9	19149-19154	their	_
110-10	19155-19163	weighted	_
110-11	19164-19168	form	_
110-12	19169-19178	following	_
110-13	19179-19183	this	_
110-14	19184-19196	thresholding	_
110-15	19197-19206	procedure	_
110-16	19207-19208	.	_

Text=Functional connectivity Group comparisons in ROI‐to‐ROI connectivity across matrices were assessed using the Networks Based Statistics (NBS) Toolbox for MATLAB (The MathWorks, Inc., Natick, Massachusetts, United States).
111-1	19209-19219	Functional	_
111-2	19220-19232	connectivity	_
111-3	19233-19238	Group	_
111-4	19239-19250	comparisons	_
111-5	19251-19253	in	_
111-6	19254-19264	ROI‐to‐ROI	_
111-7	19265-19277	connectivity	_
111-8	19278-19284	across	_
111-9	19285-19293	matrices	_
111-10	19294-19298	were	_
111-11	19299-19307	assessed	_
111-12	19308-19313	using	_
111-13	19314-19317	the	_
111-14	19318-19326	Networks	_
111-15	19327-19332	Based	_
111-16	19333-19343	Statistics	_
111-17	19344-19345	(	_
111-18	19346-19349	NBS	_
111-19	19350-19351	)	_
111-20	19352-19359	Toolbox	_
111-21	19360-19363	for	_
111-22	19364-19370	MATLAB	_
111-23	19371-19372	(	_
111-24	19373-19376	The	_
111-25	19377-19386	MathWorks	_
111-26	19387-19388	,	_
111-27	19389-19393	Inc.	_
111-28	19394-19395	,	_
111-29	19396-19402	Natick	_
111-30	19403-19404	,	_
111-31	19405-19418	Massachusetts	_
111-32	19419-19420	,	_
111-33	19421-19427	United	_
111-34	19428-19434	States	_
111-35	19435-19436	)	_
111-36	19437-19438	.	_

Text=Comparisons between the CON and ADD groups were conducted to identify those nodes across the connectome that showed differences in connectivity.
112-1	19439-19450	Comparisons	_
112-2	19451-19458	between	_
112-3	19459-19462	the	_
112-4	19463-19466	CON	_
112-5	19467-19470	and	_
112-6	19471-19474	ADD	_
112-7	19475-19481	groups	_
112-8	19482-19486	were	_
112-9	19487-19496	conducted	_
112-10	19497-19499	to	_
112-11	19500-19508	identify	_
112-12	19509-19514	those	_
112-13	19515-19520	nodes	_
112-14	19521-19527	across	_
112-15	19528-19531	the	_
112-16	19532-19542	connectome	_
112-17	19543-19547	that	_
112-18	19548-19554	showed	_
112-19	19555-19566	differences	_
112-20	19567-19569	in	_
112-21	19570-19582	connectivity	_
112-22	19583-19584	.	_

Text=Independent groups t-tests were first performed to test for a between-group difference in the correlation coefficients at each of the 110 × (110–1) /2 = 5995 regional pairings.
113-1	19585-19596	Independent	_
113-2	19597-19603	groups	_
113-3	19604-19611	t-tests	_
113-4	19612-19616	were	_
113-5	19617-19622	first	_
113-6	19623-19632	performed	_
113-7	19633-19635	to	_
113-8	19636-19640	test	_
113-9	19641-19644	for	_
113-10	19645-19646	a	_
113-11	19647-19660	between-group	_
113-12	19661-19671	difference	_
113-13	19672-19674	in	_
113-14	19675-19678	the	_
113-15	19679-19690	correlation	_
113-16	19691-19703	coefficients	_
113-17	19704-19706	at	_
113-18	19707-19711	each	_
113-19	19712-19714	of	_
113-20	19715-19718	the	_
113-21	19719-19722	110	_
113-22	19723-19724	×	_
113-23	19725-19726	(	_
113-24	19727-19732	110–1	_
113-25	19733-19734	)	_
113-26	19735-19737	/2	_
113-27	19738-19739	=	_
113-28	19740-19744	5995	_
113-29	19745-19753	regional	_
113-30	19754-19762	pairings	_
113-31	19763-19764	.	_

Text=Graph sub-components were identified among the connections using a t-statistic threshold t> 3.1.
114-1	19765-19770	Graph	_
114-2	19771-19785	sub-components	_
114-3	19786-19790	were	_
114-4	19791-19801	identified	_
114-5	19802-19807	among	_
114-6	19808-19811	the	_
114-7	19812-19823	connections	_
114-8	19824-19829	using	_
114-9	19830-19831	a	_
114-10	19832-19843	t-statistic	_
114-11	19844-19853	threshold	_
114-12	19854-19855	t	_
114-13	19856-19857	>	_
114-14	19858-19861	3.1	_
114-15	19862-19863	.	_

Text=From here, a family-wise error (FWE) corrected p-value (p <0.05) was calculated for the size of each resulting component using permutation testing (5000 permutations).
115-1	19864-19868	From	_
115-2	19869-19873	here	_
115-3	19874-19875	,	_
115-4	19876-19877	a	_
115-5	19878-19889	family-wise	_
115-6	19890-19895	error	_
115-7	19896-19897	(	_
115-8	19898-19901	FWE	_
115-9	19902-19903	)	_
115-10	19904-19913	corrected	_
115-11	19914-19921	p-value	_
115-12	19922-19923	(	_
115-13	19924-19925	p	_
115-14	19926-19927	<	_
115-15	19928-19932	0.05	_
115-16	19933-19934	)	_
115-17	19935-19938	was	_
115-18	19939-19949	calculated	_
115-19	19950-19953	for	_
115-20	19954-19957	the	_
115-21	19958-19962	size	_
115-22	19963-19965	of	_
115-23	19966-19970	each	_
115-24	19971-19980	resulting	_
115-25	19981-19990	component	_
115-26	19991-19996	using	_
115-27	19997-20008	permutation	_
115-28	20009-20016	testing	_
115-29	20017-20018	(	_
115-30	20019-20023	5000	_
115-31	20024-20036	permutations	_
115-32	20037-20038	)	_
115-33	20039-20040	.	_

Text=Two (CON> ADD and ADD> CON) analyses were conducted independently on the gain anticipation> neutral anticipation contrast matrices.
116-1	20041-20044	Two	_
116-2	20045-20046	(	_
116-3	20047-20050	CON	_
116-4	20051-20052	>	_
116-5	20053-20056	ADD	_
116-6	20057-20060	and	_
116-7	20061-20064	ADD	_
116-8	20065-20066	>	_
116-9	20067-20070	CON	_
116-10	20071-20072	)	_
116-11	20073-20081	analyses	_
116-12	20082-20086	were	_
116-13	20087-20096	conducted	_
116-14	20097-20110	independently	_
116-15	20111-20113	on	_
116-16	20114-20117	the	_
116-17	20118-20122	gain	_
116-18	20123-20135	anticipation	_
116-19	20136-20137	>	_
116-20	20138-20145	neutral	_
116-21	20146-20158	anticipation	_
116-22	20159-20167	contrast	_
116-23	20168-20176	matrices	_
116-24	20177-20178	.	_

Text=Given the differences in scanners across the three sites, these NBS analyses were conducted while controlling for study site.
117-1	20179-20184	Given	_
117-2	20185-20188	the	_
117-3	20189-20200	differences	_
117-4	20201-20203	in	_
117-5	20204-20212	scanners	_
117-6	20213-20219	across	_
117-7	20220-20223	the	_
117-8	20224-20229	three	_
117-9	20230-20235	sites	_
117-10	20236-20237	,	_
117-11	20238-20243	these	_
117-12	20244-20247	NBS	_
117-13	20248-20256	analyses	_
117-14	20257-20261	were	_
117-15	20262-20271	conducted	_
117-16	20272-20277	while	_
117-17	20278-20289	controlling	_
117-18	20290-20293	for	_
117-19	20294-20299	study	_
117-20	20300-20304	site	_
117-21	20305-20306	.	_

Text=NBS has previously been used to identify specific networks of nodes across a connectome that differ between clinical populations during different psychological processes.
118-1	20307-20310	NBS	_
118-2	20311-20314	has	_
118-3	20315-20325	previously	_
118-4	20326-20330	been	_
118-5	20331-20335	used	_
118-6	20336-20338	to	_
118-7	20339-20347	identify	_
118-8	20348-20356	specific	_
118-9	20357-20365	networks	_
118-10	20366-20368	of	_
118-11	20369-20374	nodes	_
118-12	20375-20381	across	_
118-13	20382-20383	a	_
118-14	20384-20394	connectome	_
118-15	20395-20399	that	_
118-16	20400-20406	differ	_
118-17	20407-20414	between	_
118-18	20415-20423	clinical	_
118-19	20424-20435	populations	_
118-20	20436-20442	during	_
118-21	20443-20452	different	_
118-22	20453-20466	psychological	_
118-23	20467-20476	processes	_
118-24	20477-20478	.	_

Text=Network visualisation Networks that emerged from group comparisons in NBS were visualised and presented using brain connectivity maps and circular connectograms using the NeuroMArVL software (www.immersive.erc.monash.edu.au/neuromarvl).
119-1	20479-20486	Network	_
119-2	20487-20500	visualisation	_
119-3	20501-20509	Networks	_
119-4	20510-20514	that	_
119-5	20515-20522	emerged	_
119-6	20523-20527	from	_
119-7	20528-20533	group	_
119-8	20534-20545	comparisons	_
119-9	20546-20548	in	_
119-10	20549-20552	NBS	_
119-11	20553-20557	were	_
119-12	20558-20568	visualised	_
119-13	20569-20572	and	_
119-14	20573-20582	presented	_
119-15	20583-20588	using	_
119-16	20589-20594	brain	_
119-17	20595-20607	connectivity	_
119-18	20608-20612	maps	_
119-19	20613-20616	and	_
119-20	20617-20625	circular	_
119-21	20626-20639	connectograms	_
119-22	20640-20645	using	_
119-23	20646-20649	the	_
119-24	20650-20660	NeuroMArVL	_
119-25	20661-20669	software	_
119-26	20670-20671	(	_
119-27	20672-20714	www.immersive.erc.monash.edu.au/neuromarvl	_
119-28	20715-20716	)	_
119-29	20717-20718	.	_

